Amyris (AMRSQ) 10-Q 7 Oct 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Sep. 26, 2019
Document Information [Line Items]
Entity Registrant Name	AMYRIS, INC.
Entity Central Index Key	0001365916
Trading Symbol	amrs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		103,400,207
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 940	$ 45,353
Restricted cash	493	741
Accounts receivable, net of allowance of $112 and $642	15,805	16,003
Accounts receivable - related party, net of allowance of $26 and $0	3,696	1,349
Accounts receivable, unbilled - related party		8,021
Inventories	13,961	9,693
Deferred cost of products sold - related party	1,489	489
Prepaid expenses and other current assets	9,801	10,566
Total current assets	46,185	92,215
Property, plant and equipment, net	24,260	19,756
Accounts receivable, unbilled, noncurrent - related party	1,203	1,203
Deferred cost of products sold, noncurrent - related party	15,894	2,828
Restricted cash, noncurrent	960	960
Recoverable taxes from Brazilian government entities	3,100	3,005
Right-of-use assets under leases (Note 2)	25,542
Other assets	5,672	7,958
Total assets	122,816	127,925
Current liabilities:
Accounts payable	31,459	26,844
Accrued and other current liabilities	28,113	28,979
Lease liabilities (Note 2)	9,918
Contract liabilities	12,737	8,236
Debt, current portion (instrument measured at fair value $72,461 and $57,918, respectively)	79,429	124,010
Related party debt, current portion	28,220	23,667
Total current liabilities	189,876	211,736
Long-term debt, net of current portion	10,494	43,331
Related party debt, net of current portion	50,601	18,689
Lease liabilities, net of current portion (Note 2)	17,215
Derivative liabilities		42,796
Other noncurrent liabilities	29,964	23,192
Total liabilities	298,150	339,744
Commitments and contingencies (Note 8)
Contingently redeemable common stock (Note 5)	5,000	5,000
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of June 30, 2019 and December 31, 2018, and 14,656 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
Common stock - $0.0001 par value, 250,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 101,186,738 and 76,564,829 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	10	8
Additional paid-in capital	1,479,415	1,346,996
Accumulated other comprehensive loss	(43,479)	(43,343)
Accumulated deficit	(1,617,217)	(1,521,417)
Total Amyris, Inc. stockholders’ deficit	(181,271)	(217,756)
Noncontrolling interest	937	937
Total stockholders' deficit	(180,334)	(216,819)
Total liabilities, mezzanine equity and stockholders' deficit	$ 122,816	$ 127,925

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accounts receivable, allowance	$ 112,000	$ 642,000
Accounts receivable, related party, allowance	26,000	0
Debt, current portion, fair value	$ 72,461	$ 57,918
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	14,656	14,656
Preferred stock, shares outstanding (in shares)	14,656	14,656
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	101,186,738	76,564,829
Common stock, shares outstanding (in shares)	101,186,738	76,564,829

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue:
Revenues	$ 62,694,000	$ 15,059,000	$ 77,068,000	$ 32,918,000
Cost and operating expenses:
Cost of products sold	15,121,000	6,534,000	32,828,000	11,849,000
Research and development	19,222,000	15,669,000	37,061,000	33,494,000
Sales, general and administrative	30,862,000	19,454,000	59,115,000	37,554,000
Total cost and operating expenses	65,205,000	41,657,000	129,004,000	82,897,000
Loss from operations	(2,511,000)	(26,598,000)	(51,936,000)	(49,979,000)
Other income (expense):
Loss on divestiture				(1,778,000)
Interest expense	(15,217,000)	(9,580,000)	(27,751,000)	(19,558,000)
(Loss) gain from change in fair value of derivative instruments		21,990,000	(2,039,000)	(36,367,000)
Loss from change in fair value of debt	(14,444,000)		(16,574,000)
Gain (Loss) on Extinguishment of Debt, Total	(5,875,000)	(26,000)	(5,875,000)	(26,000)
Other income (expense), net	(41,000)	(168,000)	(156,000)	524,000
Total other income (expense), net	(35,577,000)	12,216,000	(52,395,000)	(57,205,000)
Loss before income taxes	(38,088,000)	(14,382,000)	(104,331,000)	(107,184,000)
Provision for income taxes
Net loss attributable to Amyris, Inc.	(38,088,000)	(14,382,000)	(104,331,000)	(107,184,000)
Less: deemed dividend related to proceeds discount and issuance costs upon conversion of Series D	(34,964,000)		(34,964,000)
Add: losses allocated to participating securities	2,255,000	970,000	4,690,000	7,932,000
Net loss attributable to Amyris, Inc. common stockholders	$ (70,797,000)	$ (13,412,000)	$ (134,605,000)	$ (99,252,000)
Loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.76)	$ (0.24)	$ (1.59)	$ (1.87)
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares)	92,785,752	54,932,411	84,831,269	53,076,975
Product [Member]
Revenue:
Revenues	$ 12,120,000	$ 6,633,000	$ 24,004,000	$ 11,828,000
Licenses and Royalties [Member]
Revenue:
Revenues	40,964,000	(513,000)	41,082,000	7,442,000
Grants and Collaborations [Member]
Revenue:
Revenues	$ 9,610,000	$ 8,939,000	$ 11,982,000	$ 13,648,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues, related party	$ 43,328	$ 1,369	$ 43,346	$ 10,171
Product [Member]
Revenues, related party	0	144	2	295
Licenses and Royalties [Member]
Revenues, related party	40,682	(513)	40,302	7,405
Grants and Collaborations [Member]
Revenues, related party	$ 2,646	$ 1,738	$ 3,042	$ 2,471

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Comprehensive loss:
Net loss attributable to Amyris, Inc.	$ (38,088)	$ (14,382)	$ (104,331)	$ (107,184)
Foreign currency translation adjustment	(1,100)	(827)	(136)	(964)
Comprehensive loss attributable to Amyris, Inc.	$ (39,188)	$ (15,209)	$ (104,467)	$ (108,148)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Mezzanine Equity, Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	22,171	45,637,433
Balance at Dec. 31, 2017		$ 5	$ 1,114,546	$ (42,156)	$ (1,290,420)	$ 937	$ 5,000	$ (217,088)
Cumulative effect of change in accounting principle (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017					(803)			(803)
Issuance of common stock upon exercise of warrants (in shares)		162,392
Issuance of common stock upon exercise of warrants			835					835
Issuance of common stock upon exercise of stock options (in shares)		7,004
Issuance of common stock upon exercise of stock options			81					81
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)		30,489
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock			(66)					(66)
Stock-based compensation			1,278					1,278
Foreign currency translation adjustment				(137)				(137)
Net loss attributable to Amyris, Inc.					(92,802)			(92,802)
Issuance of common stock in private placement (in shares)		13,529
Issuance of common stock in private placement			92					92
Other			93					93
Balance (in shares) at Mar. 31, 2018	22,171	45,850,847
Balance at Mar. 31, 2018		$ 5	1,116,859	(42,293)	(1,384,025)	937	5,000	(308,517)
Balance (in shares) at Dec. 31, 2017	22,171	45,637,433
Balance at Dec. 31, 2017		$ 5	1,114,546	(42,156)	(1,290,420)	937	5,000	(217,088)
Cumulative effect of change in accounting principle (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017					(803)			(803)
Net loss attributable to Amyris, Inc.								(107,184)
Balance (in shares) at Jun. 30, 2018	19,334	50,340,680
Balance at Jun. 30, 2018		$ 5	1,154,625	(43,120)	(1,398,407)	937	5,000	(285,960)
Balance (in shares) at Mar. 31, 2018	22,171	45,850,847
Balance at Mar. 31, 2018		$ 5	1,116,859	(42,293)	(1,384,025)	937	5,000	(308,517)
Issuance of common stock upon exercise of warrants (in shares)		3,638,938
Issuance of common stock upon exercise of warrants			24,788					24,788
Issuance of common stock upon exercise of stock options (in shares)		36,051
Issuance of common stock upon exercise of stock options			195					195
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)		85,130
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock			(147)					(147)
Stock-based compensation			1,900					1,900
Foreign currency translation adjustment				(827)				(827)
Net loss attributable to Amyris, Inc.					(14,382)			(14,382)
Issuance of common stock in private placement (in shares)		191,639
Issuance of common stock in private placement			1,323					1,323
Issuance of common stock upon ESPP purchase (in shares)		87,768
Issuance of common stock upon ESPP purchase			269					269
Issuance of warrants in connection with debt accounted for at fair value			9,438					9,438
Issuance of common stock upon conversion of preferred stock (in shares)	(2,837)	450,307
Issuance of common stock upon conversion of preferred stock
Balance (in shares) at Jun. 30, 2018	19,334	50,340,680
Balance at Jun. 30, 2018		$ 5	1,154,625	(43,120)	(1,398,407)	937	5,000	$ (285,960)
Balance (in shares) at Dec. 31, 2018	14,656	76,564,829						76,564,829
Balance at Dec. 31, 2018		$ 8	1,346,996	(43,343)	(1,521,417)	937	5,000	$ (216,819)
Cumulative effect of change in accounting principle (Accounting Standards Update 2017-01 [Member]) at Dec. 31, 2018			32,512		8,531			41,043
Issuance of common stock upon exercise of warrants (in shares)		450,568
Issuance of common stock upon exercise of warrants			1					1
Issuance of common stock upon exercise of stock options (in shares)		3,612
Issuance of common stock upon exercise of stock options			13					13
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)		191,672
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock			(9)					(9)
Stock-based compensation			3,452					3,452
Fair value of bifurcated embedded conversion feature in connection with debt modification			398					398
Foreign currency translation adjustment				964				964
Net loss attributable to Amyris, Inc.					(66,243)			(66,243)
Balance (in shares) at Mar. 31, 2019	14,656	77,210,681
Balance at Mar. 31, 2019		$ 8	1,383,363	(42,379)	(1,579,129)	937	5,000	$ (237,200)
Balance (in shares) at Dec. 31, 2018	14,656	76,564,829						76,564,829
Balance at Dec. 31, 2018		$ 8	1,346,996	(43,343)	(1,521,417)	937	5,000	$ (216,819)
Cumulative effect of change in accounting principle (Accounting Standards Update 2017-01 [Member]) at Dec. 31, 2018			32,512		8,531			$ 41,043
Issuance of common stock upon exercise of warrants (in shares)								2,515,174
Issuance of common stock upon exercise of stock options (in shares)								3,612
Net loss attributable to Amyris, Inc.								$ (104,331)
Balance (in shares) at Jun. 30, 2019	14,656	101,186,738
Balance at Jun. 30, 2019		$ 10	1,479,415	(43,479)	(1,617,217)	937	5,000	(180,334)
Balance (in shares) at Mar. 31, 2019	14,656	77,210,681
Balance at Mar. 31, 2019		$ 8	1,383,363	(42,379)	(1,579,129)	937	5,000	$ (237,200)
Issuance of common stock upon exercise of warrants (in shares)		2,064,606						2,064,606
Issuance of common stock upon exercise of warrants
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)		589,241
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock			(347)					(347)
Stock-based compensation			3,375					3,375
Foreign currency translation adjustment				(1,100)				(1,100)
Net loss attributable to Amyris, Inc.					(38,088)			(38,088)
Issuance of common stock in private placement (in shares)		3,610,944
Issuance of common stock in private placement		$ 1	14,221					14,222
Issuance of common stock in private placement - related party (in shares)		10,478,338
Issuance of common stock in private placement - related party			39,499					39,499
Issuance of common stock upon conversion of debt (in shares)		7,101,468
Issuance of common stock upon conversion of debt		$ 1	34,650					34,651
Issuance of common stock upon ESPP purchase (in shares)		131,460
Issuance of common stock upon ESPP purchase			464					464
Issuance of warrants in connection with debt accounted for at fair value			4,428					4,428
Other			(238)					(238)
Balance (in shares) at Jun. 30, 2019	14,656	101,186,738
Balance at Jun. 30, 2019		$ 10	$ 1,479,415	$ (43,479)	$ (1,617,217)	$ 937	$ 5,000	$ (180,334)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	Jan. 01, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Operating activities
Net loss		$ (38,088,000)	$ (66,243,000)	$ (14,382,000)	$ (92,802,000)	$ (104,331,000)	$ (107,184,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from change in fair value of debt		14,444,000				16,574,000		$ (2,082,000)
Amortization of debt discount						7,260,000	8,229,000
Stock-based compensation						6,827,000	3,178,000
Loss upon extinguishment of debt						5,875,000	26,000
Expense for warrants issued for covenant waivers						4,428,000
Amortization of right-of-use assets under operating leases						5,846,000
Loss from change in fair value of derivative liability						2,039,000	36,367,000
Depreciation and amortization						1,722,000	2,944,000
Write-down of property, plant and equipment						438,000
(Gain) loss on disposal of property, plant and equipment						(4,000)	942,000
Gain on foreign currency exchange rates						(36,000)	(31,000)
Changes in assets and liabilities:
Accounts receivable						(2,147,000)	10,956,000
Accounts receivable, unbilled – related party						8,021,000	(5,150,000)
Inventories						(4,310,000)	(1,313,000)
Deferred cost of products sold						(14,066,000)
Prepaid expenses and other assets						(1,000,000)	(1,678,000)
Accounts payable						4,532,000	3,087,000
Accrued and other liabilities						7,659,000	(6,720,000)
Lease liabilities						(8,096,000)
Contract liabilities						4,512,000	1,859,000
Net cash used in operating activities						(58,257,000)	(54,488,000)
Investing activities
Change in short-term investments							(157,000)
Purchases of property, plant and equipment						(5,951,000)	(4,207,000)
Net cash used in investing activities						(5,951,000)	(4,364,000)
Financing activities
Proceeds from issuance of common stock in private placements, net of issuance costs - related party						39,500,000
Proceeds from issuance of common stock in private placements, net of issuance costs						14,221,000	1,416,000
Proceeds from issuance of debt, net of issuance costs						18,614,000	36,105,000
Proceeds from issuance of common stock upon ESPP purchase						464,000	270,000
Proceeds from exercises of common stock options						13,000	248,000
Proceeds from exercises of warrants						1,000	14,549,000
Principal payments on debt						(52,145,000)	(37,037,000)
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units						(356,000)	(185,000)
Principal payments on financing leases						(258,000)	(593,000)
Net cash provided by financing activities						20,054,000	14,773,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash						(507,000)	(78,000)
Net decrease in cash, cash equivalents and restricted cash						(44,661,000)	(44,157,000)
Cash, cash equivalents and restricted cash at beginning of period	$ 47,054,000		$ 47,054,000		$ 61,012,000	47,054,000	61,012,000	61,012,000
Cash, cash equivalents and restricted cash at end of the period		2,393,000		16,855,000		2,393,000	16,855,000	47,054,000
Cash and cash equivalents		940,000		14,050,000		940,000	14,050,000	45,353,000
Restricted cash, current		493,000		1,846,000		493,000	1,846,000	741,000
Restricted cash, noncurrent		$ 960,000		$ 959,000		960,000	959,000	$ 960,000
Supplemental disclosures of cash flow information:
Cash paid for interest						7,986,000	8,634,000
Supplemental disclosures of non-cash investing and financing activities:
Right-of-use assets under operating leases recorded upon adoption of ASC 842 (Note 2)						29,713,000
Lease liabilities recorded upon adoption of ASC 842 (Note 2)						33,552,000
Cumulative effect of change in accounting principle for ASU 2017-11 (Note 2)						41,043,000
Issuance of common stock upon conversion of convertible notes						34,650,000
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable						1,026,000	744,000
Acquisition of right-of-use assets under operating leases	$ 29,700,000					1,675,000
Accrued interest added to debt principal						448,000	1,894,000
Fair value of warrants recorded as debt discount in connection with debt modification						$ 398,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Amyris, Inc. (Amyris or the Company) is a leading industrial biotechnology company that applies its technology platform to engineer, manufacture and sell high performance, natural, sustainably-sourced products into the Health & Wellness, Clean Beauty, and Flavor & Fragrance markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company has successfully used its technology to develop and produce many distinct molecules at commercial volumes. The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10 December 31, 2018 2018 10 December 31, 2018 10 10 X. not not Raizen Joint Venture Agreement On May 10, 2019, not December 31, 2019, may not Upon the closing of the joint venture, each party will make an initial capital contribution to the joint venture of 2,500,000 R$2,500,000 50% 50% 60 U.S.$9.0 U.S.$3.0 six 10 After the formation of the joint venture, subject to certain exceptions, the parties will not not third seventh The Company is evaluating the accounting treatment for its future interest in the joint venture under ASC 810, 323, Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 June 30, 2019, $143.7 $119.5 December 31, 2018 $1.6 As of June 30, 2019, $13.1 $168.7 $107.6 June 30, 2019, 12, June 30, 2020 $128.9 $21.3 June 30, 2019, September 16, 2019, $63.6 12, $143.7 $143.7 not not no not Cash and cash equivalents of $0.9 June 30, 2019 not June 30, 2020. one not 12 June 30, 2020 December 31, 2018, may may not On September 16, 2019, $63.6 The Company does not not no no not not Significant Accounting Policies Note 1, 2018 10 no three six June 30, 2019, January 1, 2019: • Accounting Standards Codification (ASC) Topic 842 842 Leases; • ASU 2017 11, Earnings Per Share (Topic 260 480 815 Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 2018 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Contract liability arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not For descriptions of the Company's other significant accounting policies, see the 2018 10 Accounting Standards or Updates Recently Adopted In the six June 30, 2019, Leases February 2016, No. 2016 02, Leases (Topic 842 July 2018, 2018 11, Leases (Topic 842 842 The Company adopted this standard on January 1, 2019 1 2 3 not not not not not 12 not The adoption of this standard had the net effect of increasing both assets and liabilities by $25.7 not 1 2 Upon adoption, the Company recognized operating lease liabilities of $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019, 2017 11 $32.5 $8.5 $41.0 Recent Accounting Standards or Updates Not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	2. Inventories (In thousands) June 30, 2019 December 31, 2018 Raw materials $ 4,389 $ 3,901 Work-in-process 1,697 539 Finished goods 7,875 5,253 Inventories $ 13,961 $ 9,693 Deferred cost of products sold - related party (In thousands) June 30, 2019 December 31, 2018 Deferred cost of products sold - related party $ 1,489 $ 489 Deferred cost of products sold, noncurrent - related party 15,894 2,828 Total $ 17,383 $ 3,317 In November 2018, 1 2022. 10, 8 2018 10 November 2018 $24.4 $3.3 December 31, 2018. six June 30, 2019, $14.1 $6.9 five December 2018, June 30, 2019. Prepaid expenses and other current assets (In thousands) June 30, 2019 December 31, 2018 Prepayments, advances and deposits $ 3,147 $ 5,644 Recoverable taxes from Brazilian government entities 1,787 631 Other 4,867 4,291 Total prepaid expenses and other current assets $ 9,801 $ 10,566 Property, Plant and Equipment, Net (In thousands) June 30, 2019 December 31, 2018 Machinery and equipment $ 47,553 $ 43,713 Leasehold improvements 40,817 39,922 Computers and software 10,307 9,987 Furniture and office equipment, vehicles and land 3,349 3,016 Construction in progress 2,245 1,749 104,271 98,387 Less: accumulated depreciation and amortization (80,011 ) (78,631 ) Property, plant and equipment, net $ 24,260 $ 19,756 During the three six June 30, 2019 2018, (In thousands) Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Capitalized internally-developed software $ 120 $ 800 $ 320 $ 1,580 During the three six June 30, 2019 2018, (In thousands) Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Depreciation and amortization expense $ 873 $ 1,383 $ 1,722 $ 2,944 Leases Operating Leases The Company has entered into operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 5 one 1 5 June 30, 2019 June 30, 2019 $29.7 $33.6 January 1, 2019. January 1, 2019 June 30, 2019, $25.5 $26.7 three six June 30, 2019, $3.0 $5.8 $1.8 $3.6 Because the rate implicit in each lease is not may Information related to the Company's right-of-use assets and related lease liabilities were as follows: (In thousands) Six Months Ended Cash paid for operating lease liabilities $ 10,660 Right-of-use assets obtained in exchange for new operating lease obligations (1) $ 31,293 Weighted-average remaining lease term (in years) 2.6 Weighted-average discount rate 18.0 % ( 1 $29.7 January 1, 2019 $1.6 six June 30, 2019. Financing Leases The Company has entered into financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Property, plant and equipment, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Property, plant and equipment, net includes $5.3 $5.0 June 30, 2019 December 31, 2018, $2.7 $2.3 June 30, 2019 December 31, 2018, Maturities of Financing and Operating Leases Maturities of lease liabilities as of June 30, 2019 Years ending December 31: Financing Operating Total Leases 2019 (remaining six months) $ 235 $ 8,027 $ 8,262 2020 199 9,660 9,859 2021 1 7,227 7,228 2022 – 7,400 7,400 2023 – 3,034 3,034 Thereafter – – – Total lease payments 435 35,348 35,783 Less: amount representing interest (14 ) (8,636 ) (8,650 ) Total lease liability $ 421 $ 26,712 $ 27,133 Current lease liability $ 385 $ 9,533 $ 9,918 Noncurrent lease liability 36 17,179 17,215 Total lease liability $ 421 $ 26,712 $ 27,133 Other Assets (In thousands) June 30, 2019 December 31, 2018 Contingent consideration $ 4,286 $ 4,286 Deposits 297 2,465 Other 1,089 1,207 Other assets $ 5,672 $ 7,958 Accrued and Other Current Liabilities (In thousands) June 30, 2019 December 31, 2018 Accrued interest $ 6,876 $ 3,853 Payroll and related expenses 6,164 9,220 Contract termination fees 4,342 6,247 Asset retirement obligation 3,232 3,063 Tax-related liabilities 2,434 2,139 Professional services 1,302 1,173 Other 3,763 3,284 Total accrued and other current liabilities $ 28,113 $ 28,979 Other noncurrent liabilities (In thousands) June 30, 2019 December 31, 2018 Refund liability $ 12,500 $ – Contract liability, net of current portion (Note 9) 1,449 1,587 Contract termination fees, net of current portion 8,678 7,715 Liability for unrecognized tax benefit 6,582 6,582 Other 755 868 Deferred rent, net of current portion (1) – 6,440 Total other noncurrent liabilities $ 29,964 $ 23,192 ( 1 December 31, 2018 January 1, 2019 842,

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	3. Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) June 30, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities 6% Convertible Notes Due 2021 $ – $ – $ 72,461 $ 72,461 $ – $ – $ 57,918 $ 57,918 Freestanding derivative instruments in connection with the issuance of debt and equity instruments – – – – – – 42,796 42,796 Total liabilities measured and recorded at fair value $ – $ – $ 72,461 $ 72,461 $ – $ – $ 100,714 $ 100,714 There were no 6% 2021 The Company issued $60.0 6% 2021 December 10, 2018 June 30, 2019, $58.0 $72.5 125% 4, six June 30, 2019, $16.6 6% 2021, In thousands Fair value at December 31, 2018 $ 57,918 Less: principal paid (2,031 ) Loss on change in fair value 16,574 Fair value at June 30, 2019 $ 72,461 Derivative Liabilities Recognized in Connection with the Issuance of Debt and Equity Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt and equity instruments, measured at fair value using significant unobservable inputs (Level 3 (In thousands) Equity-related Debt-related Total Derivative Balance at December 31, 2018 $ 41,272 $ 1,524 $ 42,796 Derecognition upon adoption of ASU 2017-11 (39,513 ) (1,524 ) (41,037 ) Change in fair value of derivative liabilities 2,039 – 2,039 Derecognition on extinguishment (3,798 ) – (3,798 ) Balance at June 30, 2019 $ – $ – $ – As of June 30, 2019, November 2018 Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value (except for the 6% 2021, 2 3 June 30, 2019, 6% $96.3 June 30, 2019 $98.6 third

Note 4 - Debt

Note 4 - Debt	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Net carrying amounts of debt are as follows: June 30, 2019 December 31, 2018 (In thousands) Principal Unamortized Change Net Balance Principal Unamortized Change Net Balance Convertible notes payable 6% convertible notes due 2021 $ 57,969 $ – $ 14,492 $ 72,461 $ 60,000 $ – $ (2,082 ) $ 57,918 August 2013 financing convertible note 4,863 (90 ) – 4,773 4,415 (70 ) – 4,345 2015 Rule 144A convertible notes – – – – 37,887 (2,413 ) – 35,474 2014 Rule 144A convertible notes – – – – 24,004 (867 ) – 23,137 62,832 (90 ) 14,492 77,234 126,306 (3,350 ) (2,082 ) 120,874 Related party convertible notes payable 2014 Rule 144A convertible notes 9,705 – – 9,705 24,705 (1,038 ) – 23,667 Loans payable and credit facilities Ginkgo note 12,000 (3,609 ) – 8,391 12,000 (4,047 ) – 7,953 Other loans payable 5,323 (973 ) – 4,350 4,910 (1,047 ) – 3,863 GACP secured term loan facility – – – – 36,000 (1,349 ) – 34,651 17,323 (4,582 ) – 12,741 52,910 (6,443 ) – 46,467 Related party loans payable Foris secured term loan facility 36,000 (3,054 ) – 32,946 – – – – Foris unsecured notes 16,500 – – 16,500 – – – – DSM note 25,000 (5,382 ) – 19,618 25,000 (6,311 ) – 18,689 $ 77,500 $ (8,436 ) $ – 69,064 $ 25,000 $ (6,311 ) $ – 18,689 Total debt $ 167,360 $ (13,108 ) $ 14,492 168,744 $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 Less: current portion (107,649 ) (147,677 ) Long-term debt, net of current portion $ 61,095 $ 62,020 The 6% 2021 June 30, 2019 December 31, 2018 June 30, 2019 June 30, 2019 December 31, 2018 12, August 2013 On January 14, 2019, August 2013 January 15, 2019 July 15, 2019 July 15, 2019, $0.6 July 15, 2019, October 13, 2019 1.75% July 16, 2019 On July 2, 2019, August 2013 1,767,632 1,080,000 12, LSA Amendment, Assignment and Waiver On April 4, 2019, June 29, 2018 ( December 31, 2018, July 1, 2021, ( $15 On April 4, 2019, December 31, 2018 April 8, 2019, $0.8 April 2019. On April 15, 2019, five $2.2 April 16, 2019. 12, On August 14, 2019, No 5 July 1, 2021 July 1, 2022, ( x 4.75% 9% 12% December 16, 2019, ( December 16, 2019, ( April 8, 2019, June 11, 2019, July 10, 2019 July 26, 2019 ( $32.5 $71.0 August 14, 2019 1,438,829 $2.87 two may not 19.99% 2019 Foris Credit Agreements On April 8, 2019, $8.0 April April 8, 2019 $8.0 April April October 14, 2019, no $1.0 April April April $0.5 April July 15, 2019. April $4.8 4, On June 11, 2019, $8.5 June 11, 2019 $8.5 June June 12.5% June 11, 2019, June August 28, 2019; June The Company may April April June 100% June On August 14, 2019, April June July 12, 12, 2015 2014 144A On April 16, 2019, $37.9 2015 144A On May 10, 2019, $13.5 2014 144A 3,479,008 1,391,603 $5.02 two 3 9 1933, 6. On May 14, 2019, $5.0 2014 144A 1,122,460 352,638 $4.56 two 3 9 6. On May 15, 2019, $10.0 2014 144A 2,500,000 3 9 6. The Company evaluated the May 2019 $5.9 2014 144A three June 30, 2019. $30.8 $3.8 $0.4 $29.1 7.1 $4.27 $4.54; $4.56 $5.02; 95.8%; 2.20% 2.26%; 0%. On May 15, 2019, $9.7 2014 144A June 14, 2019, 3 9 June 14, 2019, June 14, 2019 July 18, 2019. no no three June 30, 2019. July 18, 2019, July 18, 2019 August 28, 2019 10.5% July 18, 2019. August 28, 2019, August 28, 2019 October 28, 2019 12% August 28, 2019. 6% 2021 On May 15, 2019 June 24, 2019, $53.3 $4.7 6% 2021, 6% 2021, 2,000,000 181,818 $5.12 two 3 9 6% 2021 July 22, 2019, July 22, 2019 July 29, 2019, 125% $4.4 94% 96% 1.72% 2.16% 2 $3.55 $4.39 0% The Company has elected the fair value accounting option for the 6% 2021 6% 2021. not six not may not may not 4.99% 12, 6% 2021. Future Minimum Payments Future minimum payments under the Company's debt agreements as of June 30, 2019 (In thousands) Convertible Loans Related Related Total 2019 (remaining six months) $ 81,006 $ 3,748 $ 9,815 $ 24,674 $ 119,243 2020 3,926 1,759 — 10,854 16,539 2021 2,318 1,662 — 61,260 65,240 2022 — 13,451 — — 13,451 2023 — 399 — — 399 Thereafter — 2,268 — — 2,268 Total future minimum payments 87,250 23,287 9,815 96,788 217,140 Less: amount representing interest (9,680 ) (5,964 ) (110 ) (19,288 ) (35,042 ) Less: future conversion of accrued interest to principal (246 ) — — — (246 ) Present value of minimum debt payments 77,324 17,323 9,705 77,500 181,852 Less: current portion of debt principal and fair value adjustment (77,324 ) (2,392 ) (9,705 ) (20,100 ) (109,521 ) Noncurrent portion of debt principal $ — $ 14,931 $ — $ 57,400 $ 72,331

Note 5 - Mezzanine Equity

Note 5 - Mezzanine Equity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Mezzanine Equity Disclosure [Text Block]	5. Mezzanine equity at June 30, 2019 December 31, 2018 May 10, 2016 not third $17.10 10%. As of June 30, 2019, $0.5

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Private Placements On April 16, 2019, 6,732,369 $2.87 $20.0 5,424,804 $2.87 two 4 2 $20.0 On April 26, 2019, 2,832,440 $5.12 3,983,230 $5.12 two 2,043,781 $4.02 1,635,025 $5.02 two 4 2 $15.0 $8.2 $23.2 On April 29, 2019, 913,529 $4.76 1,212,787 $4.76 two five one 323,382 $4.02 258,704 $5.02 two 4 2 $4.5 $1.3 $5.8 On May 3, 2019, 1,243,781 $4.02 995,024 $5.02 two 4 2 $5 The exercise price of the warrants issued in the foregoing private placements is subject to standard adjustments but does not six not not not 19.99% 2019 2014 144A On May 10, 2019, $13.5 2014 144A 3,479,008 1,391,603 $5.02 two 3 9 4, On May 14, 2019, $5.0 2014 144A May 15, 2019, 1,122,460 352,638 $4.56 two 3 9 4, On May 15, 2019, $10.0 2014 144A 2,500,000 3 9 4, The exercise price of the warrants issued in the foregoing exchanges is subject to standard adjustments but does not six not 2019 may not 4.99% Warrants In connection with various debt and equity transactions (see Note 5, 7, 8 2018 10 three six June 30, 2019: Transaction Number Additional Exercises Number Additional Exercises Number August 2018 warrant exercise agreements 12,097,164 – – 12,097,164 – – 12,097,164 May 2017 cash and dilution warrants 6,292,798 – – 6,292,798 4,795,924 (1,924,673 ) 9,164,049 April 2019 PIPE warrants – – – – 8,084,770 – 8,084,770 August 2017 cash and dilution warrants 3,968,116 – – 3,968,116 3,028,983 – 6,997,099 April 2019 Foris warrant – – – – 5,424,804 – 5,424,804 April 2018 warrant exercise agreements 3,616,174 – – 3,616,174 – – 3,616,174 May-June 2019 6% Note Exchange Warrants – – – – 2,181,818 – 2,181,818 May 2019 6.50% Note Exchange Warrants – – – – 1,744,241 – 1,744,241 July 2015 related party debt exchange 663,228 – (471,204 ) 192,024 245,558 (245,558 ) 192,024 February 2016 related party private placement 171,429 – – 171,429 – – 171,429 July 2015 private placement 81,197 – (8,547 ) 72,650 – – 72,650 Other 1,406 – – 1,406 – – 1,406 26,891,512 – (479,751 ) 26,411,761 25,506,098 (2,170,231 ) 49,747,628 Due to certain down-round adjustments to other equity-related instruments during the three June 30, 2019, 8.1 May 2017 August 2017 2.2 zero 2,064,606 2,515,174 three six June 30, 2019.

Note 7 - Loss Per Share

Note 7 - Loss Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	7. For the three six June 30, 2019 June 30, 2018, The Company follows the two two two The following table presents the calculation of basic and diluted loss per share: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except shares and per share amounts) 2019 2018 2019 2018 Numerator: Net loss attributable to Amyris, Inc. $ (38,088 ) $ (14,382 ) $ (104,331 ) $ (107,184 ) Less: deemed dividend related to proceeds discount and issuance costs upon conversion of Series D (34,964 ) — (34,964 ) — Add: losses allocated to participating securities 2,255 970 4,690 7,932 Net loss attributable to Amyris, Inc. common stockholders $ (70,797 ) $ (13,412 ) $ (134,605 ) $ (99,252 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 92,785,752 54,932,411 84,831,269 53,076,975 Loss per share attributable to common stockholders, basic and diluted $ (0.76 ) $ (0.24 ) $ (1.59 ) $ (1.87 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Period-end stock options to purchase common stock 5,535,538 5,424,330 5,535,538 5,424,330 Convertible promissory notes (1) 11,007,316 8,390,819 11,007,316 8,390,819 Period-end common stock warrants 49,747,628 24,341,772 49,747,628 24,341,772 Period-end restricted stock units 5,284,742 5,211,584 5,284,742 5,211,584 Period-end preferred stock 2,955,732 4,053,905 2,955,732 4,053,905 Total potentially dilutive securities excluded from computation of diluted loss per share 74,530,956 47,422,410 74,530,956 47,422,410 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Contingencies Disclosure [Text Block]	8. Contingencies The Company has levied indirect taxes on sugarcane-based biodiesel sales that took place several years ago by Amyris Brasil Ltda. (see Note 13, 8 2018 10 On April 3, 2019, March 15, 2018 March 19, 2019. June 21, 2019 October 1, 2019, two No. 4:19 03621 No. 4:19 06230 not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not not

Note 9 - Revenue Recognition an

Note 9 - Revenue Recognition and Contract Assets and Liabilities	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	9. Disaggregation of Revenue The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses and Grants and Total United States $ 5,806 $ – $ 6,408 $ 12,214 $ 2,339 $ – $ 4,624 $ 6,963 Europe 2,102 40,964 3,197 46,263 2,987 (513 ) 4,315 6,789 Asia 3,899 – – 3,899 1,113 – – 1,113 South America 295 – 5 300 194 – – 194 Other 18 – – 18 – – – – $ 12,120 $ 40,964 $ 9,610 $ 62,694 $ 6,633 $ (513 ) $ 8,939 $ 15,059 Six Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses and Grants and Total United States $ 12,879 $ – $ 6,901 $ 19,780 $ 4,301 $ – $ 5,832 $ 10,133 Europe 4,956 41,082 4,826 50,864 5,421 7,442 7,816 20,679 Asia 5,617 – 250 5,867 1,791 – – 1,791 South America 515 – 5 520 215 – – 215 Other 37 – – 37 100 – – 100 $ 24,004 $ 41,082 $ 11,982 $ 77,068 $ 11,828 $ 7,442 $ 13,648 $ 32,918 Significant Revenue Agreements During the Six Months Ended June 30, 2019 Cannabinoid Agreement On May 2, 2019, $300 $300 20 May 2, 2019, 5, 8 2018 10 The Cannabinoid Agreement is accounted for as a revenue contract under ASC 606, 606 $85 $215 not June 30, 2019. $10.0 second 2018 $3.5 three six June 30, 2019 $6.5 June 30, 2019, DSM Agreements On April 16, 2019, December 2017 $57.0 $7.4 third March 29, 2019 ( 10, 8 2018 10 April 16, 2019, $21.7 $27.9 2017 November 2018 No. 1 2017 11, 8 2018 10 April 16, 2019 606, $37.1 $12.5 $37.1 three six June 30, 2019, $12.5 $3.6 December 2017 April 16, 2019 In addition, on April 16, 2019 2017 2017 December 2017 10, 13, in Part II, Item 8 2018 10 2021, no In connection with the significant revenue agreements discussed above and others previously disclosed (see Note 10, 8 2018 10 , the Company recognized the following revenues for the three six June 30, 2019 2018 : Three Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses Grants and Total DSM - related party $ – $ 40,682 $ 2,646 $ 43,328 $ – $ (513 ) $ 1,737 $ 1,224 Givaudan 1,240 – – 1,240 2,109 – 1,358 3,467 Firmenich – 282 277 559 – – 1,219 1,219 DARPA – – 2,721 2,721 – – 4,191 4,191 Subtotal revenue from significant revenue agreements 1,240 40,964 5,644 47,848 2,109 (513 ) 8,505 10,101 Revenue from all other customers 10,880 – 3,966 14,846 4,524 – 434 4,958 Total revenue from all customers $ 12,120 $ 40,964 $ 9,610 $ 62,694 $ 6,633 $ (513 ) $ 8,939 $ 15,059 Six Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses Grants and Total DSM - related party $ 2 $ 40,302 $ 3,042 $ 43,346 $ – $ 7,405 $ 2,470 $ 9,875 Givaudan 2,815 – – 2,815 3,184 – 2,859 6,043 Firmenich 1,891 780 1,005 3,676 207 37 2,486 2,730 DARPA – – 2,909 2,909 – – 5,038 5,038 Subtotal revenue from significant revenue agreements 4,708 41,082 6,956 52,746 3,391 7,442 12,853 23,686 Revenue from all other customers 19,296 – 5,026 24,322 8,437 – 795 9,232 Total revenue from all customers $ 24,004 $ 41,082 $ 11,982 $ 77,068 $ 11,828 $ 7,442 $ 13,648 $ 32,918 Contract Assets and Liabilities When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade accounts receivable are recorded at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company for sale of goods or the performance of services. Contract Balances The following table provides information about accounts receivable, contract liabilities and refund liability from contracts with customers: (In thousands) June 30, December 31, Accounts receivable, net $ 15,805 $ 16,003 Accounts receivable - related party, net $ 3,696 $ 1,349 Accounts receivable, unbilled - related party $ – $ 8,021 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 1,203 Contract liabilities, current $ 12,737 $ 8,236 Contract liabilities, noncurrent (1) $ 1,449 $ 1,587 Refund liability $ 12,500 $ – ( 1 June 30, 2019 December 31, 2018, Unbilled receivables, noncurrent at both balance sheet dates relate to the Company’s right to consideration from DSM for performance fees. The Company’s right to cash receipt for these minimum royalty amounts occurs on or before December 31, 2019. December 31, 2018 June 30, 2019, $2.1 $8.0 December 31, 2019 $0.6 $7.4 $0.4 $0.2 Remaining Performance Obligations The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of June 30, 2019. (In thousands) As of June 30, 2019 Remaining 2019 $ 17,680 2020 38,508 2021 31,172 2022 and thereafter – Total from all customers $ 87,360 In accordance with the disclosure provisions of ASC 606, one $232.6

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. Related Party Debt See Note 4, June 30, 2019 December 31, 2018. Related Party Accounts Receivable and Unbilled Receivables Related party accounts receivable and unbilled receivables as of June 30, 2019 December 31, 2018 (In thousands) June 30, 2019 December 31, 2018 Accounts receivable: DSM $ 3,696 $ 1,071 Novvi – 188 Total – 90 $ 3,696 $ 1,349 Accounts receivable, unbilled, current: DSM $ – $ 8,021 Accounts receivable, unbilled, noncurrent: DSM $ 1,203 $ 1,203 Related Party Joint Ventures The Company holds a 50%

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. The Company’s stock option activity and related information for the six June 30, 2019 Quantity of Weighted- Weighted-average Aggregate Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Granted 270,633 $ 3.67 Exercised (3,612 ) $ 3.68 Forfeited or expired (121,753 ) $ 10.39 Outstanding - June 30, 2019 5,535,538 $ 11.19 8.2 $ 141 Vested or expected to vest after June 30, 2019 4,953,402 $ 11.91 8.1 $ 132 Exercisable at June 30, 2019 1,202,809 $ 32.99 6.0 $ 29 The Company’s restricted stock units (RSUs) activity and related information for the six June 30, 2019 Quantity of Weighted- Weighted- Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Awarded 1,148,866 $ 3.73 RSUs released (868,975 ) $ 5.76 RSUs forfeited (289,952 ) $ 5.62 Outstanding - June 30, 2019 5,284,742 $ 5.06 1.6 Vested or expected to vest after June 30, 2019 4,913,990 $ 5.07 1.5 Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three six June 30, 2019 2018 Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2019 2018 2019 2018 Research and development $ 676 $ 333 $ 1,339 $ 696 Sales, general and administrative 2,699 1,567 5,488 2,482 Total stock-based compensation expense $ 3,375 $ 1,900 $ 6,827 $ 3,178 As of June 30, 2019, $28.9 2.9 Evergreen Shares for 2010 2010 In February 2019, 2010 2010 3,828,241 5.0% 76,564,829 December 31, 2018. January 1, 2019. 383,824 0.5% 76,564,829 December 31, 2018. January 1, 2019.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	12. Exchange of August 2013 On July 8, 2019, August 2013 4, 1,767,632 1,080,000 3 9 not six not may not 4.99% Foris Credit Agreements On July 10, 2019, $16.0 July $8.0 July 10, 2019 $8.0 July 26, 2019 $8.0 July July 12.5% July December 31, 2019. July August 17, 2018 ( 7, 8 2018 10 $7.52 $2.87 The Company may July 100% On August 14, 2019, April 4, June 4, July On August 28, 2019, $19.0 August August 28, 2019 $19.0 August August 12% August 28, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may August 100% In connection with the entry into the August August 14, 2019 4,871,795 $3.90 two 4 2 not six not may not 19.99% 2019 Also, on August 28, 2019 August April 26, 2019 ( 6, $5.12 $3.90 May 14, 2019 ( 6, $4.56 $3.90 Exchanges of 6% 2021 On July 24, 2019, $53.3 6% 2021 4, 2,000,000 May 15, 2019, $68.3 2,000,000 $2.87 two May 15, 2019 ( 3 9 May 15, 2019, $68.3 25% July 1, 2019 $6.4 not 18% July 22, 2019 September 16, 2019, ( first October 1, 2019, ( $3.2 August 2, 2019 August 22, 2019, September 16, 2019, 8 September 16, 2019, $2.87 On July 26, 2019, one 6% 2021, $4.7 June 24, 2019, 125% July 30, 2019 August 30, 2019. August 30, 2019. On September 16, 2019, $63.6 The Company does not not no no not not Nikko Loan Agreement On July 29, 2019, $5.0 $3.0 $2.0 11, 8 2018 10 July 30, 2019, first $3.0 $2.8 $0.2 August 8, 2019, $2.0 $1.9 $0.1 December 18, 2020, ( 5% first 12.8% Aprinnova Working Capital Loan Effective July 31, 2019, 5, 2018 10 August 1, 2019 August 1, 2020. LSA Amendments and Waivers On August 14, 2019, No. 5 July 1, 2021 July 1, 2022, ( x 4.75% 9% 12% December 16, 2019, ( December 16, 2019, ( April 8, 2019, June 11, 2019, July 10, 2019 July 26, 2019 ( $32.5 $71.0 August 14, 2019 1,438,829 $2.87 two may not 19.99% 2019 Naxyris Loan and Security Agreement On August 14, 2019, $10,435,000 August 14, 2019. Loans under the Naxyris Loan Facility have a maturity date of July 1, 2022 12% 25 August 14, 2019 December 1, 2019 December 15, 2019. The obligations of the Company under the Naxyris Loan Facility are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement (as defined above). Mandatory prepayments of the outstanding amounts under the Naxyris Loan Facility will be required upon the occurrence of certain events, including asset sales, a change in control, and the incurrence of additional indebtedness, subject to certain exceptions and reinvestment rights. Outstanding amounts under the Naxyris Loan Facility must also be prepaid to the extent that the borrowing base exceeds the outstanding principal amount of the loans under the Naxyris Loan Facility. In addition, the Company may one 6% three not The affirmative and negative covenants in the Naxyris Loan Agreement relate to, among other items: (i) payment of taxes; (ii) financial reporting; (iii) maintenance of insurance; and (iv) limitations on indebtedness, liens, mergers, consolidations and acquisitions, transfers of assets, dividends and other distributions in respect of capital stock, investments, loans and advances, and corporate changes. The Naxyris Loan Agreement also contains financial covenants, including covenants related to minimum revenue, liquidity, and asset coverage. DSM Credit Agreements On September 17, 2019, “2019 $8.0 $3.0 $3.0 $2.0 September 17, 2019, first $3.0 2019 $3.0 September 19, 2019, second $3.0 2019 $3.0 September 23, 2019, $2.0 2019 $1.5 $2.0 2019 August 7, 2022, ( 12.5% January 1, April 1, July 1 October 1, January 1, 2020, first may 2019 100% 2019 May 11, 2017 August 7, 2017 ( 7, 8 2018 10 $50.0 one June 30, 2020. September 2019 On September 10, 2019, $12.5 September 10, 2019 $12.5 12% September 10, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may 100% In connection with the entry into the Investor Credit Agreements, on September 10, 2019, 3,205,128 $3.90 two 4 2 not six not no may 9.99% 60 120 no 144 not 10%, 5% 90 $3.31 $3.90 In connection with the entry into the Investor Credit Agreements and the issuance of the warrants, on September 10, 2019, no 6.99% third Ginkgo Note Amendment On September 29, 2019, November 2017 5, 10, 8 2018 10 November 2017 10.5% 12% October 1, 2019 $1.3 December 15, 2019 March 31, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Liquidity [Policy Text Block]	Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 June 30, 2019, $143.7 $119.5 December 31, 2018 $1.6 As of June 30, 2019, $13.1 $168.7 $107.6 June 30, 2019, 12, June 30, 2020 $128.9 $21.3 June 30, 2019, September 16, 2019, $63.6 12, $143.7 $143.7 not not no not Cash and cash equivalents of $0.9 June 30, 2019 not June 30, 2020. one not 12 June 30, 2020 December 31, 2018, may may not On September 16, 2019, $63.6 The Company does not not no no not not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 2018 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Contract liability arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not
New Accounting Pronouncements, Policy [Policy Text Block]	Accounting Standards or Updates Recently Adopted In the six June 30, 2019, Leases February 2016, No. 2016 02, Leases (Topic 842 July 2018, 2018 11, Leases (Topic 842 842 The Company adopted this standard on January 1, 2019 1 2 3 not not not not not 12 not The adoption of this standard had the net effect of increasing both assets and liabilities by $25.7 not 1 2 Upon adoption, the Company recognized operating lease liabilities of $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019, 2017 11 $32.5 $8.5 $41.0 Recent Accounting Standards or Updates Not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Raw materials $ 4,389 $ 3,901 Work-in-process 1,697 539 Finished goods 7,875 5,253 Inventories $ 13,961 $ 9,693
Deferred Cost of Products Sold Disclosure [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Deferred cost of products sold - related party $ 1,489 $ 489 Deferred cost of products sold, noncurrent - related party 15,894 2,828 Total $ 17,383 $ 3,317
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Prepayments, advances and deposits $ 3,147 $ 5,644 Recoverable taxes from Brazilian government entities 1,787 631 Other 4,867 4,291 Total prepaid expenses and other current assets $ 9,801 $ 10,566
Property, Plant and Equipment [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Machinery and equipment $ 47,553 $ 43,713 Leasehold improvements 40,817 39,922 Computers and software 10,307 9,987 Furniture and office equipment, vehicles and land 3,349 3,016 Construction in progress 2,245 1,749 104,271 98,387 Less: accumulated depreciation and amortization (80,011 ) (78,631 ) Property, plant and equipment, net $ 24,260 $ 19,756
Schedule of Capitalized Software [Table Text Block]	(In thousands) Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Capitalized internally-developed software $ 120 $ 800 $ 320 $ 1,580
Schedule of Depreciation and Amortization [Table Text Block]	(In thousands) Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Depreciation and amortization expense $ 873 $ 1,383 $ 1,722 $ 2,944
Lease, Cost [Table Text Block]	(In thousands) Six Months Ended Cash paid for operating lease liabilities $ 10,660 Right-of-use assets obtained in exchange for new operating lease obligations (1) $ 31,293 Weighted-average remaining lease term (in years) 2.6 Weighted-average discount rate 18.0 %
Lessee, Lease Liability, Maturity [Table Text Block]	Years ending December 31: Financing Operating Total Leases 2019 (remaining six months) $ 235 $ 8,027 $ 8,262 2020 199 9,660 9,859 2021 1 7,227 7,228 2022 – 7,400 7,400 2023 – 3,034 3,034 Thereafter – – – Total lease payments 435 35,348 35,783 Less: amount representing interest (14 ) (8,636 ) (8,650 ) Total lease liability $ 421 $ 26,712 $ 27,133 Current lease liability $ 385 $ 9,533 $ 9,918 Noncurrent lease liability 36 17,179 17,215 Total lease liability $ 421 $ 26,712 $ 27,133
Schedule of Other Assets, Noncurrent [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Contingent consideration $ 4,286 $ 4,286 Deposits 297 2,465 Other 1,089 1,207 Other assets $ 5,672 $ 7,958
Schedule of Accrued and Other Current Liabilities [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Accrued interest $ 6,876 $ 3,853 Payroll and related expenses 6,164 9,220 Contract termination fees 4,342 6,247 Asset retirement obligation 3,232 3,063 Tax-related liabilities 2,434 2,139 Professional services 1,302 1,173 Other 3,763 3,284 Total accrued and other current liabilities $ 28,113 $ 28,979
Other Noncurrent Liabilities [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Refund liability $ 12,500 $ – Contract liability, net of current portion (Note 9) 1,449 1,587 Contract termination fees, net of current portion 8,678 7,715 Liability for unrecognized tax benefit 6,582 6,582 Other 755 868 Deferred rent, net of current portion (1) – 6,440 Total other noncurrent liabilities $ 29,964 $ 23,192

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities 6% Convertible Notes Due 2021 $ – $ – $ 72,461 $ 72,461 $ – $ – $ 57,918 $ 57,918 Freestanding derivative instruments in connection with the issuance of debt and equity instruments – – – – – – 42,796 42,796 Total liabilities measured and recorded at fair value $ – $ – $ 72,461 $ 72,461 $ – $ – $ 100,714 $ 100,714
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	In thousands Fair value at December 31, 2018 $ 57,918 Less: principal paid (2,031 ) Loss on change in fair value 16,574 Fair value at June 30, 2019 $ 72,461
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(In thousands) Equity-related Debt-related Total Derivative Balance at December 31, 2018 $ 41,272 $ 1,524 $ 42,796 Derecognition upon adoption of ASU 2017-11 (39,513 ) (1,524 ) (41,037 ) Change in fair value of derivative liabilities 2,039 – 2,039 Derecognition on extinguishment (3,798 ) – (3,798 ) Balance at June 30, 2019 $ – $ – $ –

Note 4 - Debt (Tables)

Note 4 - Debt (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Debt [Table Text Block]	June 30, 2019 December 31, 2018 (In thousands) Principal Unamortized Change Net Balance Principal Unamortized Change Net Balance Convertible notes payable 6% convertible notes due 2021 $ 57,969 $ – $ 14,492 $ 72,461 $ 60,000 $ – $ (2,082 ) $ 57,918 August 2013 financing convertible note 4,863 (90 ) – 4,773 4,415 (70 ) – 4,345 2015 Rule 144A convertible notes – – – – 37,887 (2,413 ) – 35,474 2014 Rule 144A convertible notes – – – – 24,004 (867 ) – 23,137 62,832 (90 ) 14,492 77,234 126,306 (3,350 ) (2,082 ) 120,874 Related party convertible notes payable 2014 Rule 144A convertible notes 9,705 – – 9,705 24,705 (1,038 ) – 23,667 Loans payable and credit facilities Ginkgo note 12,000 (3,609 ) – 8,391 12,000 (4,047 ) – 7,953 Other loans payable 5,323 (973 ) – 4,350 4,910 (1,047 ) – 3,863 GACP secured term loan facility – – – – 36,000 (1,349 ) – 34,651 17,323 (4,582 ) – 12,741 52,910 (6,443 ) – 46,467 Related party loans payable Foris secured term loan facility 36,000 (3,054 ) – 32,946 – – – – Foris unsecured notes 16,500 – – 16,500 – – – – DSM note 25,000 (5,382 ) – 19,618 25,000 (6,311 ) – 18,689 $ 77,500 $ (8,436 ) $ – 69,064 $ 25,000 $ (6,311 ) $ – 18,689 Total debt $ 167,360 $ (13,108 ) $ 14,492 168,744 $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 Less: current portion (107,649 ) (147,677 ) Long-term debt, net of current portion $ 61,095 $ 62,020
Schedule of Long-term Debt Instruments [Table Text Block]	(In thousands) Convertible Loans Related Related Total 2019 (remaining six months) $ 81,006 $ 3,748 $ 9,815 $ 24,674 $ 119,243 2020 3,926 1,759 — 10,854 16,539 2021 2,318 1,662 — 61,260 65,240 2022 — 13,451 — — 13,451 2023 — 399 — — 399 Thereafter — 2,268 — — 2,268 Total future minimum payments 87,250 23,287 9,815 96,788 217,140 Less: amount representing interest (9,680 ) (5,964 ) (110 ) (19,288 ) (35,042 ) Less: future conversion of accrued interest to principal (246 ) — — — (246 ) Present value of minimum debt payments 77,324 17,323 9,705 77,500 181,852 Less: current portion of debt principal and fair value adjustment (77,324 ) (2,392 ) (9,705 ) (20,100 ) (109,521 ) Noncurrent portion of debt principal $ — $ 14,931 $ — $ 57,400 $ 72,331

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Transaction Number Additional Exercises Number Additional Exercises Number August 2018 warrant exercise agreements 12,097,164 – – 12,097,164 – – 12,097,164 May 2017 cash and dilution warrants 6,292,798 – – 6,292,798 4,795,924 (1,924,673 ) 9,164,049 April 2019 PIPE warrants – – – – 8,084,770 – 8,084,770 August 2017 cash and dilution warrants 3,968,116 – – 3,968,116 3,028,983 – 6,997,099 April 2019 Foris warrant – – – – 5,424,804 – 5,424,804 April 2018 warrant exercise agreements 3,616,174 – – 3,616,174 – – 3,616,174 May-June 2019 6% Note Exchange Warrants – – – – 2,181,818 – 2,181,818 May 2019 6.50% Note Exchange Warrants – – – – 1,744,241 – 1,744,241 July 2015 related party debt exchange 663,228 – (471,204 ) 192,024 245,558 (245,558 ) 192,024 February 2016 related party private placement 171,429 – – 171,429 – – 171,429 July 2015 private placement 81,197 – (8,547 ) 72,650 – – 72,650 Other 1,406 – – 1,406 – – 1,406 26,891,512 – (479,751 ) 26,411,761 25,506,098 (2,170,231 ) 49,747,628

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (In thousands, except shares and per share amounts) 2019 2018 2019 2018 Numerator: Net loss attributable to Amyris, Inc. $ (38,088 ) $ (14,382 ) $ (104,331 ) $ (107,184 ) Less: deemed dividend related to proceeds discount and issuance costs upon conversion of Series D (34,964 ) — (34,964 ) — Add: losses allocated to participating securities 2,255 970 4,690 7,932 Net loss attributable to Amyris, Inc. common stockholders $ (70,797 ) $ (13,412 ) $ (134,605 ) $ (99,252 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 92,785,752 54,932,411 84,831,269 53,076,975 Loss per share attributable to common stockholders, basic and diluted $ (0.76 ) $ (0.24 ) $ (1.59 ) $ (1.87 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Period-end stock options to purchase common stock 5,535,538 5,424,330 5,535,538 5,424,330 Convertible promissory notes (1) 11,007,316 8,390,819 11,007,316 8,390,819 Period-end common stock warrants 49,747,628 24,341,772 49,747,628 24,341,772 Period-end restricted stock units 5,284,742 5,211,584 5,284,742 5,211,584 Period-end preferred stock 2,955,732 4,053,905 2,955,732 4,053,905 Total potentially dilutive securities excluded from computation of diluted loss per share 74,530,956 47,422,410 74,530,956 47,422,410

Note 9 - Revenue Recognition _2

Note 9 - Revenue Recognition and Contract Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses and Grants and Total United States $ 5,806 $ – $ 6,408 $ 12,214 $ 2,339 $ – $ 4,624 $ 6,963 Europe 2,102 40,964 3,197 46,263 2,987 (513 ) 4,315 6,789 Asia 3,899 – – 3,899 1,113 – – 1,113 South America 295 – 5 300 194 – – 194 Other 18 – – 18 – – – – $ 12,120 $ 40,964 $ 9,610 $ 62,694 $ 6,633 $ (513 ) $ 8,939 $ 15,059 Six Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses and Grants and Total United States $ 12,879 $ – $ 6,901 $ 19,780 $ 4,301 $ – $ 5,832 $ 10,133 Europe 4,956 41,082 4,826 50,864 5,421 7,442 7,816 20,679 Asia 5,617 – 250 5,867 1,791 – – 1,791 South America 515 – 5 520 215 – – 215 Other 37 – – 37 100 – – 100 $ 24,004 $ 41,082 $ 11,982 $ 77,068 $ 11,828 $ 7,442 $ 13,648 $ 32,918
Revenue in Connection with Significant Revenue Agreement [Table Text Block]	Three Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses Grants and Total DSM - related party $ – $ 40,682 $ 2,646 $ 43,328 $ – $ (513 ) $ 1,737 $ 1,224 Givaudan 1,240 – – 1,240 2,109 – 1,358 3,467 Firmenich – 282 277 559 – – 1,219 1,219 DARPA – – 2,721 2,721 – – 4,191 4,191 Subtotal revenue from significant revenue agreements 1,240 40,964 5,644 47,848 2,109 (513 ) 8,505 10,101 Revenue from all other customers 10,880 – 3,966 14,846 4,524 – 434 4,958 Total revenue from all customers $ 12,120 $ 40,964 $ 9,610 $ 62,694 $ 6,633 $ (513 ) $ 8,939 $ 15,059 Six Months Ended June 30, (In thousands) 2019 2018 Renewable Licenses and Grants and Total Renewable Licenses Grants and Total DSM - related party $ 2 $ 40,302 $ 3,042 $ 43,346 $ – $ 7,405 $ 2,470 $ 9,875 Givaudan 2,815 – – 2,815 3,184 – 2,859 6,043 Firmenich 1,891 780 1,005 3,676 207 37 2,486 2,730 DARPA – – 2,909 2,909 – – 5,038 5,038 Subtotal revenue from significant revenue agreements 4,708 41,082 6,956 52,746 3,391 7,442 12,853 23,686 Revenue from all other customers 19,296 – 5,026 24,322 8,437 – 795 9,232 Total revenue from all customers $ 24,004 $ 41,082 $ 11,982 $ 77,068 $ 11,828 $ 7,442 $ 13,648 $ 32,918
Contract with Customer, Asset and Liability [Table Text Block]	(In thousands) June 30, December 31, Accounts receivable, net $ 15,805 $ 16,003 Accounts receivable - related party, net $ 3,696 $ 1,349 Accounts receivable, unbilled - related party $ – $ 8,021 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 1,203 Contract liabilities, current $ 12,737 $ 8,236 Contract liabilities, noncurrent (1) $ 1,449 $ 1,587 Refund liability $ 12,500 $ –
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	(In thousands) As of June 30, 2019 Remaining 2019 $ 17,680 2020 38,508 2021 31,172 2022 and thereafter – Total from all customers $ 87,360

Note 10 - Related Party Trans_2

Note 10 - Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Related Party Accounts Receivables [Table Text Block]	(In thousands) June 30, 2019 December 31, 2018 Accounts receivable: DSM $ 3,696 $ 1,071 Novvi – 188 Total – 90 $ 3,696 $ 1,349 Accounts receivable, unbilled, current: DSM $ – $ 8,021 Accounts receivable, unbilled, noncurrent: DSM $ 1,203 $ 1,203

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]	Quantity of Weighted- Weighted-average Aggregate Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Granted 270,633 $ 3.67 Exercised (3,612 ) $ 3.68 Forfeited or expired (121,753 ) $ 10.39 Outstanding - June 30, 2019 5,535,538 $ 11.19 8.2 $ 141 Vested or expected to vest after June 30, 2019 4,953,402 $ 11.91 8.1 $ 132 Exercisable at June 30, 2019 1,202,809 $ 32.99 6.0 $ 29
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Quantity of Weighted- Weighted- Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Awarded 1,148,866 $ 3.73 RSUs released (868,975 ) $ 5.76 RSUs forfeited (289,952 ) $ 5.62 Outstanding - June 30, 2019 5,284,742 $ 5.06 1.6 Vested or expected to vest after June 30, 2019 4,913,990 $ 5.07 1.5
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2019 2018 2019 2018 Research and development $ 676 $ 333 $ 1,339 $ 696 Sales, general and administrative 2,699 1,567 5,488 2,482 Total stock-based compensation expense $ 3,375 $ 1,900 $ 6,827 $ 3,178

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	Sep. 16, 2019USD ($)	May 10, 2019BRL (R$)	Jan. 01, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Working Capital				$ (143,700,000)	$ (119,500,000)
Retained Earnings (Accumulated Deficit), Ending Balance				(1,617,217,000)	(1,521,417,000)
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total				13,100,000
Long-term Debt, Total				168,744,000	209,697,000
Long-term Debt, Current Maturities, Including Due to Related Parties				107,649,000	147,677,000
Long-term Debt, Current Maturities Due Within 60 Days, Including Due to Related Parties				128,900,000
Long-term Debt, Current Maturities Due Within 60 Days, Including Due to Related Parties, Anticipated Interest Portion				21,300,000
Cash, Cash Equivalents, and Short-term Investments, Total				900,000
Assets, Total				122,816,000	127,925,000
Operating Lease, Liability, Total				26,712,000
Operating Lease, Right-of-Use Asset				25,542,000
Liabilities, Total				$ 298,150,000	$ 339,744,000
Accounting Standards Update 2016-02 [Member]
Assets, Total			$ 25,700,000
Operating Lease, Liability, Total			33,600,000
Operating Lease, Right-of-Use Asset			29,700,000
Liabilities, Total			24,900,000
Accounting Standards Update 2017-11 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			(8,500,000)
Additional Paid in Capital, Ending Balance			32,500,000
Increase (Decrease) in Derivative Liabilities			$ (41,000,000)
Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member] | Subsequent Event [Member]
Debt Instrument, Debt Default, Amount	$ 63,600,000
Extinguishment of Debt, Amount	$ 143,700,000
The Joint Venture [Member]
Payments to Acquire Interest in Joint Venture | R$		R$ 2500000
Equity Method Investment, Ownership Percentage		50.00%
The Joint Venture [Member] | Raizen [Member]
Equity Method Investment, Ownership Percentage		50.00%

Note 2 - Balance Sheet Detail_2

Note 2 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	Jan. 01, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Deferred Cost of Products Sold, Related Party		$ 17,383	$ 17,383		$ 3,317
Operating Lease, Right-of-Use Asset		25,542	25,542
Operating Lease, Liability, Total		26,712	26,712
Operating Lease, Expense		3,000	5,800
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 29,700		1,675
Finance Lease, Right-of-use Asset, Accumulated Amortization		2,700	2,700		2,300
Property, Plant and Equipment, Net [Member]
Finance Lease, Right-of-Use Asset		5,300	5,300		5,000
Cost of Sales [Member]
Operating Lease, Expense		$ 1,800	$ 3,600
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset	29,700
Operating Lease, Liability, Total	$ 33,600
Minimum [Member]
Lessee Operating Lease, Remaining Lease Term			1 year
Lessee, Operating Lease, Renewal Term		1 year	1 year
Maximum [Member]
Lessee Operating Lease, Remaining Lease Term			5 years
Lessee, Operating Lease, Renewal Term		5 years	5 years
DSM International B.V. [Member]
Manufacturing Capacity Reservation Fee Current					24,400
Deferred Cost of Products Sold, Related Party		$ 6,900	$ 6,900		$ 3,300
Payments of Reservation Capacity Fees			$ 14,100

Note 2 - Balance Sheet Detail_3

Note 2 - Balance Sheet Details - Inventory, Current (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Raw materials	$ 4,389	$ 3,901
Work-in-process	1,697	539
Finished goods	7,875	5,253
Inventories	$ 13,961	$ 9,693

Note 2 - Balance Sheet Detail_4

Note 2 - Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Deferred cost of products sold - related party	$ 1,489	$ 489
Deferred cost of products sold, noncurrent - related party	15,894	2,828
Total	$ 17,383	$ 3,317

Note 2 - Balance Sheet Detail_5

Note 2 - Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Prepayments, advances and deposits	$ 3,147	$ 5,644
Recoverable taxes from Brazilian government entities	1,787	631
Other	4,867	4,291
Total prepaid expenses and other current assets	$ 9,801	$ 10,566

Note 2 - Balance Sheet Detail_6

Note 2 - Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property, plant and equipment	$ 104,271	$ 98,387
Less: accumulated depreciation and amortization	(80,011)	(78,631)
Property, plant and equipment, net	24,260	19,756
Machinery and Equipment [Member]
Property, plant and equipment	47,553	43,713
Leasehold Improvements [Member]
Property, plant and equipment	40,817	39,922
Computer Equipment and Software [Member]
Property, plant and equipment	10,307	9,987
Furniture and Office Equipment, Vehicles and Land [Member]
Property, plant and equipment	3,349	3,016
Construction in Progress [Member]
Property, plant and equipment	$ 2,245	$ 1,749

Note 2 - Balance Sheet Detail_7

Note 2 - Balance Sheet Details - Capitalized Software (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Capitalized internally-developed software	$ 120	$ 800	$ 320	$ 1,580

Note 2 - Balance Sheet Detail_8

Note 2 - Balance Sheet Details - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Depreciation and amortization expense	$ 873	$ 1,383	$ 1,722	$ 2,944

Note 2 - Balance Sheet Detail_9

Note 2 - Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Cash paid for operating lease liabilities	$ 10,660
Right-of-use assets obtained in exchange for new operating lease obligations(1)	$ 31,293	[1]
Weighted-average remaining lease term (in years) (Year)	2 years 219 days
Weighted-average discount rate	18.00%
[1]	Includes $29.7 million for operating leases existing on January 1, 2019 and $1.6 million for operating leases that commenced during the six months ended June 30, 2019.

Note 2 - Balance Sheet Detai_10

Note 2 - Balance Sheet Details - Maturities of Financing and Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
2019 (remaining nine months), financing leases	$ 235
2019 (remaining nine months), operating leases	8,027
2019 (remaining nine months), total leases	8,262
2020, financing leases	199
2020, operating leases	9,660
2020, total leases	9,859
2021, financing leases	1
2021, operating leases	7,227
2021, total leases	7,228
2022, financing leases
2022, operating leases	7,400
2022, total leases	7,400
2023, financing leases
2023, operating leases	3,034
2023, total leases	3,034
Thereafter, financing leases
Thereafter, operating leases
Thereafter, total leases
Total lease payments, financing leases	435
Total lease payments, operating leases	35,348
Total lease payments, total leases	35,783
Less: amount representing interest	(14)
Less: amount representing interest	(8,636)
Less: amount representing interest	(8,650)
Total lease liability, financing leases	421
Total lease liability, operating leases	26,712
Total lease liability, total leases	27,133
Current lease liability, financing leases	385
Current lease liability, operating leases	9,533
Lease liabilities (Note 2)	9,918
Noncurrent lease liability, financing leases	36
Noncurrent lease liability, operating leases	17,179
Lease liabilities, net of current portion (Note 2)	$ 17,215

Note 2 - Balance Sheet Detai_11

Note 2 - Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Contingent consideration	$ 4,286	$ 4,286
Deposits	297	2,465
Other	1,089	1,207
Other assets	$ 5,672	$ 7,958

Note 2 - Balance Sheet Detai_12

Note 2 - Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accrued interest	$ 6,876	$ 3,853
Payroll and related expenses	6,164	9,220
Contract termination fees	4,342	6,247
Asset retirement obligation	3,232	3,063
Tax-related liabilities	2,434	2,139
Professional services	1,302	1,173
Other	3,763	3,284
Total accrued and other current liabilities	$ 28,113	$ 28,979

Note 2 - Balance Sheet Detai_13

Note 2 - Balance Sheet Details - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Refund liability		$ 12,500
Contract liability, net of current portion (Note 9)		1,449	1,587
Contract termination fees, net of current portion		8,678	7,715
Liability for unrecognized tax benefit		6,582	6,582
Other		755	868
Deferred rent, net of current portion(1)	[1]		6,440
Total other noncurrent liabilities		$ 29,964	$ 23,192
[1]	Deferred rent at December 31, 2018 was reclassified to ROU asset upon the adoption on January 1, 2019 of ASC 842, "Leases".

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurement (Details Textual)	6 Months Ended
	Jun. 30, 2019USD ($)	Jul. 26, 2019	Dec. 31, 2018USD ($)	Dec. 10, 2018USD ($)
Long-term Debt, Gross	$ 167,360,000		$ 228,921,000
Long-term Debt, Fair Value	72,461		$ 57,918
Debt, Long-term and Short-term, Combined Amount, Total	96,300,000
Debt Instrument, Fair Value Disclosure, Total	98,600,000
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Debt Instrument, Face Amount				$ 60,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%	6.00%	6.00%
Long-term Debt, Gross	58,000,000
Long-term Debt, Fair Value	72,500,000
Fair Value Adjustment of Debt	$ (16,600,000)
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Put Option Price [Member]
Long-term Debt, Measurement Input	1.25

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Debt, current portion, fair value	$ 72,461	$ 57,918
Fair Value, Recurring [Member]
Debt, current portion, fair value	72,461,000	57,918,000
Freestanding derivative instruments in connection with the issuance of debt and equity instruments		42,796,000
Total liabilities measured and recorded at fair value	72,461,000	100,714,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Debt, current portion, fair value
Freestanding derivative instruments in connection with the issuance of debt and equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Debt, current portion, fair value
Freestanding derivative instruments in connection with the issuance of debt and equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Debt, current portion, fair value	72,461,000	57,918,000
Freestanding derivative instruments in connection with the issuance of debt and equity instruments		42,796,000
Total liabilities measured and recorded at fair value	$ 72,461,000	$ 100,714,000

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurement - Convertible Debt (Details) - Long-term Debt [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Fair value	$ 57,918
Less: principal paid	(2,031)
Loss on change in fair value	16,574
Fair value	$ 72,461

Note 3 - Fair Value Measureme_6

Note 3 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Fair value	$ 42,796
Derecognition upon adoption of ASU 2017-11	(41,037)
Loss on change in fair value	2,039
Less: principal paid	(3,798)
Fair value
Equity Securities [Member]
Fair value	41,272
Derecognition upon adoption of ASU 2017-11	(39,513)
Loss on change in fair value	2,039
Less: principal paid	(3,798)
Fair value
Debt Securities [Member]
Fair value	1,524
Derecognition upon adoption of ASU 2017-11	(1,524)
Loss on change in fair value
Less: principal paid
Fair value

Note 4 - Debt (Details Textual)

Note 4 - Debt (Details Textual)	Aug. 14, 2019USD ($)$ / sharesshares	Jul. 26, 2019USD ($)	Jul. 24, 2019USD ($)shares	Jul. 02, 2019shares	Jun. 24, 2019USD ($)shares	May 15, 2019USD ($)$ / sharesshares	May 14, 2019USD ($)$ / sharesshares	May 10, 2019USD ($)$ / sharesshares	Apr. 16, 2019USD ($)	Apr. 15, 2019USD ($)	Apr. 04, 2019USD ($)	Jun. 24, 2019USD ($)shares	Jun. 30, 2019USD ($)shares	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)shares	Jun. 30, 2018USD ($)	Aug. 28, 2019$ / shares	Jul. 18, 2019	Jul. 15, 2019	Jun. 11, 2019USD ($)	May 31, 2019	Apr. 08, 2019USD ($)	Apr. 01, 2019USD ($)	Mar. 31, 2019shares	Jan. 14, 2019USD ($)	Dec. 31, 2018USD ($)shares	Dec. 10, 2018USD ($)
Long-term Debt, Gross													$ 167,360,000		$ 167,360,000											$ 228,921,000
Gain (Loss) on Extinguishment of Debt, Total													$ (5,875,000)	$ (26,000)	(5,875,000)	$ (26,000)
Debt Conversion, Converted Instrument, Amount															$ 34,650,000
Class of Warrant or Right, Outstanding | shares													49,747,628		49,747,628									26,411,761		26,891,512
Interest Expense, Total													$ 15,217,000	$ 9,580,000	$ 27,751,000	$ 19,558,000
Foris Ventures, LLC [Member]
Related Party Transaction, Purchases from Related Party										$ 2,200,000
Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member] | Other Non-affiliated Investors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 5.02
Debt Conversion, Converted Instrument, Warrants Issued | shares								1,391,603
Class of Warrant or Right, Term								2 years
Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member] | Foris Ventures, LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 4.56										$ 3.90
Debt Conversion, Original Debt, Amount						$ 10,000,000
Debt Conversion, Converted Instrument, Warrants Issued | shares							352,638
Class of Warrant or Right, Term							2 years
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member]
Class of Warrant or Right, Outstanding | shares													3,800,000		3,800,000
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																					95.8
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																					0
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Minimum [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																					4.56
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																					2.2
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																					4.27
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Maximum [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																					5.02
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																					2.26
Warrants Issued in Connection with Rule 144A Convertible Notes Conversion [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																					4.54
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					181,818	2,000,000						181,818
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 5.12
Debt Instrument, Repayment Price, Percent of Face Amount						4.99%
Class of Warrant or Right, Term					2 years
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0							0
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input					2							2
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input					94							94
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input					1.72							1.72
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input					3.55							3.55
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input					96							96
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input					2.16							2.16
Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input					4.39							4.39
Rule 144A Convertible Notes Converted to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares													7,100,000
Debt Conversion, Original Debt, Amount													$ 29,100,000
Debt Conversion, Converted Instrument, Amount													30,800,000
Debt Issuance Costs, Net, Total																							$ 400,000
Subsequent Event [Member] | Warrants in Connection of Extinguishment of Tranche II Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				1,080,000
Subsequent Event [Member] | LSA Amendment Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	1,438,829
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.87
Warrants and Rights Outstanding, Term	2 years
Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage	19.99%
Subsequent Event [Member] | Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			2,000,000
Subsequent Event [Member] | Common Stock Issued upon Extinguishment of Tranche II Note [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares				1,767,632
Second Tranche [Member] | Related Party Convertible Notes [Member]
Debt Instrument, Cash Waiver Fee Amount Payable																									$ 600,000
Second Tranche [Member] | Related Party Convertible Notes [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage																			1.75%
Loan and Security Agreement [Member] | Great American Capital Partners, LLC [Member]
Debt Instrument, Requirement, Unrestricted, Unencumbered Cash											$ 15,000,000
Payments for debt agreement amendment											$ 800,000
Loan and Security Agreement Amendment and Waiver [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Long-term Debt, Gross	$ 71,000,000
Loan and Security Agreement Amendment and Waiver [Member] | Subsequent Event [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	9.00%
Loan and Security Agreement Amendment and Waiver [Member] | Subsequent Event [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	12.00%
Loan and Security Agreement Amendment and Waiver [Member] | Unsecured Promissory Note [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount	$ 32,500,000
April Foris Credit Agreement [Member] | Foris Ventures, LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage																						0.00%
Debt Instrument, Face Amount																						$ 8,000,000
Line of Credit Facility, Maximum Borrowing Capacity																						8,000,000
Debt Instrument, Fee Amount																						1,000,000
April Foris Credit Agreement [Member] | Foris Ventures, LLC [Member] | Maximum [Member]
Debt Instrument, Fee Amount																						500,000
Tranche II Notes [Member] | Subordinated Debt [Member]
Debt Instrument, Face Amount																						$ 4,800,000
June Foris Credit Agreement [Member] | Foris Ventures, LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage																				12.50%
Debt Instrument, Face Amount																				$ 8,500,000
Line of Credit Facility, Maximum Borrowing Capacity																				$ 8,500,000
Debt Instrument, Repayment Price, Percent of Face Amount																				100.00%
Rule 144A Convertible Notes [Member]
Gain (Loss) on Extinguishment of Debt, Total													5,900,000
Rule 144A Convertible Notes [Member] | Other Non-affiliated Investors [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares								3,479,008
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 5.02
Repayments of Debt									$ 37,900,000
Debt Conversion, Original Debt, Amount								$ 13,500,000
Debt Conversion, Converted Instrument, Warrants Issued | shares								1,391,603
Rule 144A Convertible Notes [Member] | Foris Ventures, LLC [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares							1,122,460
Debt Conversion, Original Debt, Amount							$ 5,000,000
Rule 144A Convertible Notes [Member] | Maxwell (Mauritius) Pte Ltd [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares						2,500,000
Debt Conversion, Original Debt, Amount						$ 10,000,000
Rule 144A Convertible Notes [Member] | Total [Member]
Debt Conversion, Original Debt, Amount						$ 9,700,000
Rule 144A Convertible Notes [Member] | Subsequent Event [Member] | Total [Member]
Debt Instrument, Interest Rate, Stated Percentage																	12.00%	10.50%
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Debt Instrument, Interest Rate, Stated Percentage		6.00%																								6.00%	6.00%
Debt Instrument, Face Amount																											$ 60,000,000
Long-term Debt, Gross													$ 58,000,000		$ 58,000,000
Debt Instrument, Repayment Price, Percent of Face Amount		125.00%				125.00%
Debt Conversion, Original Debt, Amount		$ 4,700,000			$ 4,700,000	$ 53,300,000
Interest Expense, Total												$ 4,400,000
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount			$ 68,300,000
Debt Conversion, Original Debt, Amount			$ 53,300,000

Note 4 - Debt - Debt Components

Note 4 - Debt - Debt Components (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Principal	$ 167,360,000		$ 167,360,000		$ 228,921,000
Unamortized Debt Premium	(13,108,000)		(13,108,000)		(17,142,000)
Loss from change in fair value of debt	14,444,000		16,574,000		(2,082,000)
Net Balance	168,744,000		168,744,000		209,697,000
Net Balance	(107,649,000)		(107,649,000)		(147,677,000)
Net Balance	61,095,000		61,095,000		62,020,000
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Principal	58,000,000		58,000,000
Convertible Debt [Member]
Principal	62,832,000		62,832,000		126,306,000
Unamortized Debt Premium	(90,000)		(90,000)		(3,350,000)
Loss from change in fair value of debt			14,492,000		(2,082,000)
Net Balance	77,234,000		77,234,000		120,874,000
Convertible Debt [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member]
Principal	57,969,000		57,969,000		60,000,000
Unamortized Debt Premium
Loss from change in fair value of debt			14,492,000		(2,082,000)
Net Balance	72,461,000		72,461,000		57,918,000
Convertible Debt [Member] | August 2013 Convertible Notes [Member]
Principal	4,863,000		4,863,000		4,415,000
Unamortized Debt Premium	(90,000)		(90,000)		(70,000)
Loss from change in fair value of debt
Net Balance	4,773,000		4,773,000		4,345
Convertible Debt [Member] | The 2015 144A Notes [Member]
Principal					37,887,000
Unamortized Debt Premium					(2,413,000)
Loss from change in fair value of debt
Net Balance					35,474,000
Convertible Debt [Member] | The 2014 144A Notes [Member]
Principal					24,004,000
Unamortized Debt Premium					(867,000)
Loss from change in fair value of debt
Net Balance					23,137,000
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member]
Principal	9,705,000		9,705,000		24,705,000
Unamortized Debt Premium					(1,038,000)
Loss from change in fair value of debt
Net Balance	9,705,000		9,705,000		23,667,000
Loans Payable [Member]
Principal	17,323,000		17,323,000		52,910,000
Unamortized Debt Premium	(4,582,000)		(4,582,000)		(6,443,000)
Loss from change in fair value of debt
Net Balance	12,741,000		12,741,000		46,467,000
Loans Payable [Member] | Ginkgo Collaboration Note [Member]
Principal	12,000,000		12,000,000		12,000,000
Unamortized Debt Premium	(3,609,000)		(3,609,000)		(4,047,000)
Loss from change in fair value of debt
Net Balance	8,391,000		8,391,000		7,953
Loans Payable [Member] | Other Loans Payable [Member]
Principal	5,323,000		5,323,000		4,910,000
Unamortized Debt Premium	(973,000)		(973,000)		(1,047,000)
Loss from change in fair value of debt
Net Balance	4,350,000		4,350,000		3,863,000
Nonrelated Party Debt [Member]
Principal					36,000,000
Unamortized Debt Premium					(1,349,000)
Loss from change in fair value of debt
Net Balance					34,651
Related Party Loan Payable [Member]
Principal	77,500		77,500		25,000
Unamortized Debt Premium	(8,436)		(8,436)		(6,311)
Loss from change in fair value of debt
Net Balance	69,064		69,064		18,689
Related Party Loan Payable [Member] | Foris Secured Term Loan Facility [Member]
Principal	36,000		36,000
Unamortized Debt Premium	(3,054)		(3,054)
Loss from change in fair value of debt
Net Balance	32,946		32,946
Related Party Loan Payable [Member] | Foris Unsecured Notes [Member]
Principal	16,500		16,500
Unamortized Debt Premium
Loss from change in fair value of debt
Net Balance	16,500		16,500
Related Party Loan Payable [Member] | DSM Note [Member]
Principal	25,000,000		25,000,000		25,000,000
Unamortized Debt Premium	(5,382,000)		(5,382,000)		(6,311,000)
Loss from change in fair value of debt
Net Balance	$ 19,618,000		$ 19,618,000		$ 18,689,000

Note 4 - Debt - Long-term Debt

Note 4 - Debt - Long-term Debt Instruments (Details) $ in Thousands	Jun. 30, 2019USD ($)
2019 (remaining six months)	$ 119,243
2020	16,539
2021	65,240
2022	13,451
2023	399
Thereafter	2,268
Total future minimum payments	217,140
Less: amount representing interest	(35,042)
Less: future conversion of accrued interest to principal	(246)
Present value of minimum debt payments	181,852
Less: current portion of debt principal and fair value adjustment	(109,521)
Noncurrent portion of debt principal	72,331
Convertible Debt [Member]
2019 (remaining six months)	81,006
2020	3,926
2021	2,318
2022
2023
Thereafter
Total future minimum payments	87,250
Less: amount representing interest	(9,680)
Less: future conversion of accrued interest to principal	(246)
Present value of minimum debt payments	77,324
Less: current portion of debt principal and fair value adjustment	(77,324)
Noncurrent portion of debt principal
Loans Payable and Credit Facilities [Member]
2019 (remaining six months)	3,748
2020	1,759
2021	1,662
2022	13,451
2023	399
Thereafter	2,268
Total future minimum payments	23,287
Less: amount representing interest	(5,964)
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	17,323
Less: current portion of debt principal and fair value adjustment	(2,392)
Noncurrent portion of debt principal	14,931
Related Party Convertible Notes [Member]
2019 (remaining six months)	9,815
2020
2021
2022
2023
Thereafter
Total future minimum payments	9,815
Less: amount representing interest	(110)
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	9,705
Less: current portion of debt principal and fair value adjustment	(9,705)
Noncurrent portion of debt principal
Related Party Loans Payable and Credit Facilities [Member]
2019 (remaining six months)	24,674
2020	10,854
2021	61,260
2022
2023
Thereafter
Total future minimum payments	96,788
Less: amount representing interest	(19,288)
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	77,500
Less: current portion of debt principal and fair value adjustment	(20,100)
Noncurrent portion of debt principal	$ 57,400

Note 5 - Mezzanine Equity (Deta

Note 5 - Mezzanine Equity (Details Textual) - Gates Foundation Purchase Agreement [Member] $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2019USD ($)$ / shares
Share Price | $ / shares	$ 17.10
Compound Annual Return	10.00%
Research and Development Obligation, Remaining Amount | $	$ 0.5

Note 6 - Stockholders' Defici_2

Note 6 - Stockholders' Deficit (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

May 15, 2019

May 14, 2019

May 10, 2019

May 03, 2019

Apr. 29, 2019

Apr. 26, 2019

Apr. 16, 2019

Jun. 30, 2019

Jun. 30, 2019

Jun. 30, 2018

Aug. 29, 2019

Aug. 28, 2019

Proceeds from Issuance of Private Placement

$ 14,221

$ 1,416

Proceeds from Warrant Exercises

$ 1

$ 14,549

Stock Issued During Period, Shares, Warrants Exercised

2,064,606

2,515,174

Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

4.99%

Cash and Dilution Warrants and Temasek Funding Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

8,100,000

8,100,000

Dilution Warrants [Member]

Class of Warrant or Right, Exercises During the Period

2,200,000

Proceeds from Warrant Exercises

$ 0

Foris Ventures, LLC [Member]

Proceeds from Issuance of Private Placement

$ 15,000

Foris Ventures, LLC [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 5,000

Debt Conversion, Converted Instrument, Shares Issued

1,122,460

Foris Ventures, LLC [Member] | Private Placement, April 16, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

5,424,804

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.87

Class of Warrant or Right, Term

2 years

Foris Ventures, LLC [Member] | Private Placement, April 26, 2019 [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.12

$ 3.90

Class of Warrant or Right, Term

2 years

Foris Ventures, LLC [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 4.56

$ 3.90

Class of Warrant or Right, Term

2 years

Debt Conversion, Original Debt, Amount

$ 10,000

Debt Conversion, Converted Instrument, Warrants Issued

352,638

Other Non-affiliated Investors [Member] | Rule 144A Convertible Notes [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.02

Debt Conversion, Original Debt, Amount

$ 13,500

Debt Conversion, Converted Instrument, Shares Issued

3,479,008

Debt Conversion, Converted Instrument, Warrants Issued

1,391,603

Other Non-affiliated Investors [Member] | Private Placement, April 26, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,635,025

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Other Non-affiliated Investors [Member] | Private Placement April 29, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

258,704

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Other Non-affiliated Investors [Member] | Private Placement May 3, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

995,024

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Other Non-affiliated Investors [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.02

Class of Warrant or Right, Term

2 years

Debt Conversion, Converted Instrument, Warrants Issued

1,391,603

Non-affiliated Investors [Member]

Proceeds from Issuance of Private Placement

$ 1,300

$ 8,200

Vivo Capital LLC [Member]

Proceeds from Issuance of Private Placement

$ 4,500

Vivo Capital LLC [Member] | Private Placement April 29, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,212,787

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 4.76

Warrants and Rights Outstanding, Term

2 years

Maxwell (Mauritius) Pte Ltd [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 10,000

Debt Conversion, Converted Instrument, Shares Issued

2,500,000

Private Placement [Member]

Proceeds from Issuance of Common Stock

$ 5,000

$ 5,800

$ 23,200

Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage

19.99%

Private Placement [Member] | Foris Ventures, LLC [Member]

Stock Issued During Period, Shares, New Issues

2,832,440

6,732,369

Shares Issued, Price Per Share

$ 5.12

$ 2.87

Proceeds from Issuance of Common Stock

$ 20,000

Private Placement [Member] | Foris Ventures, LLC [Member] | Private Placement, April 26, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

3,983,230

Private Placement [Member] | Other Non-affiliated Investors [Member]

Stock Issued During Period, Shares, New Issues

1,243,781

323,382

2,043,781

Shares Issued, Price Per Share

$ 4.02

$ 4.02

$ 4.02

Private Placement [Member] | Vivo Capital LLC [Member]

Stock Issued During Period, Shares, New Issues

913,529

Shares Issued, Price Per Share

$ 4.76

Note 6 - Stockholders' Defici_3

Note 6 - Stockholders' Deficit - Warrant Activity (Details) - shares	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Number outstanding (in shares)	26,411,761	26,891,512
Additional Warrants Issued (in shares)	25,506,098
Exercises (in shares)	(2,170,231)	(479,751)
Number outstanding (in shares)	49,747,628	26,411,761
Warrant 1 [Member]
Number outstanding (in shares)	12,097,164	12,097,164
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding (in shares)	12,097,164	12,097,164
Warrant 2 [Member]
Number outstanding (in shares)	6,292,798	6,292,798
Additional Warrants Issued (in shares)	4,795,924
Exercises (in shares)	(1,924,673)
Number outstanding (in shares)	9,164,049	6,292,798
Warrant 3 [Member]
Number outstanding (in shares)
Additional Warrants Issued (in shares)	8,084,770
Exercises (in shares)
Number outstanding (in shares)	8,084,770
Warrant 4 [Member]
Number outstanding (in shares)	3,968,116	3,968,116
Additional Warrants Issued (in shares)	3,028,983
Exercises (in shares)
Number outstanding (in shares)	6,997,099	3,968,116
Warrant 5 [Member]
Number outstanding (in shares)
Additional Warrants Issued (in shares)	5,424,804
Exercises (in shares)
Number outstanding (in shares)	5,424,804
Warrant 6 [Member]
Number outstanding (in shares)	3,616,174	3,616,174
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding (in shares)	3,616,174	3,616,174
Warrant 7 [Member]
Number outstanding (in shares)
Additional Warrants Issued (in shares)	2,181,818
Exercises (in shares)
Number outstanding (in shares)	2,181,818
Warrant 8 [Member]
Number outstanding (in shares)
Additional Warrants Issued (in shares)	1,744,241
Exercises (in shares)
Number outstanding (in shares)	1,744,241
Warrant 9 [Member]
Number outstanding (in shares)	192,024	663,228
Additional Warrants Issued (in shares)	245,558
Exercises (in shares)	(245,558)	(471,204)
Number outstanding (in shares)	192,024	192,024
Warrant 10 [Member]
Number outstanding (in shares)	171,429	171,429
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding (in shares)	171,429	171,429
Warrant 11 [Member]
Number outstanding (in shares)	72,650	81,197
Additional Warrants Issued (in shares)
Exercises (in shares)		(8,547)
Number outstanding (in shares)	72,650	72,650
Warrant 12 [Member]
Number outstanding (in shares)	1,406	1,406
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding (in shares)	1,406	1,406

Note 7 - Loss Per Share - Calcu

Note 7 - Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Net loss attributable to Amyris, Inc.	$ (38,088)	$ (66,243)	$ (14,382)	$ (92,802)	$ (104,331)	$ (107,184)
Less: deemed dividend related to proceeds discount and issuance costs upon conversion of Series D	(34,964)				(34,964)
Add: losses allocated to participating securities	2,255		970		4,690	7,932
Net loss attributable to Amyris, Inc. common stockholders	$ (70,797)		$ (13,412)		$ (134,605)	$ (99,252)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)	92,785,752		54,932,411		84,831,269	53,076,975
Loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.76)		$ (0.24)		$ (1.59)	$ (1.87)

Note 7 - Loss Per Share - Antid

Note 7 - Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Antidilutive securities (in shares)		74,530,956	47,422,410	74,530,956	47,422,410
Stock Options to Purchase Common Stock [Member]
Antidilutive securities (in shares)		5,535,538	5,424,330	5,535,538	5,424,330
Convertible Promissory Notes [Member]
Antidilutive securities (in shares)	[1]	11,007,316	8,390,819	11,007,316	8,390,819
Period-end Common Stock Warrants [Member]
Antidilutive securities (in shares)		49,747,628	24,341,772	49,747,628	24,341,772
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)		5,284,742	5,211,584	5,284,742	5,211,584
Period-end Preferred Stock [Member]
Antidilutive securities (in shares)		2,955,732	4,053,905	2,955,732	4,053,905
[1]	The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Revenue Recognition _3

Note 9 - Revenue Recognition and Contract Assets and Liabilities (Details Textual) - USD ($) $ in Thousands	May 02, 2019	Apr. 16, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Contract with Customer, Asset, Reclassified to Receivable					$ 2,100
Contract with Customer, Asset, after Allowance for Credit Loss, Total			$ 8,000		8,000
Cost of Goods and Services Sold, Total			15,121	$ 6,534	32,828	$ 11,849
Interest Expense, Total			15,217	9,580	27,751	19,558
Revenue, Remaining Performance Obligation, Constrained Variable Consideration, Amount			232,600		232,600
DSM International B.V. [Member]
Contract with Customer, Liability, Revenue Recognized					3,600
Contract with Customer, Liability, Total			12,500		12,500
Consideration Transferred		$ 57,000
Final Annual Royalty Payment Due Under Original Agreement		7,400
Proceeds from Customers		21,700			7,400
Amount Used to Offset Past Due Trade Payables		$ 27,900
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract			$ 37,100		37,100
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price					600
Interest Expense, Total					200
DSM International B.V. [Member] | Licenses and Royalties [Member]
Cost of Goods and Services Sold, Total					$ 400
The Cannabinoid Agreement [Member] | Lavvan [Member]
Agreement Amount	$ 300,000
Agreement, Amount of Research and Development Funding that Could Be Received	$ 300,000
Agreement, Profit Sharing to Be Received from the Counterparty, Period	20 years
Estimated Total Unconstrained Transaction Price	$ 85,000
Variable Consideration Related to Milestones	$ 215,000
Milestone Payment Received				10,000
Contract with Customer, Liability, Revenue Recognized				3,500		3,500
Contract with Customer, Liability, Total				$ 6,500		$ 6,500

Note 9 - Revenue Recognition _4

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues	$ 62,694	$ 15,059	$ 77,068	$ 32,918
Renewable Products [Member]
Revenues	12,120	6,633	24,004	11,828
Licenses and Royalties [Member]
Revenues	40,964	(513)	41,082	7,442
Grants and Collaborations [Member]
Revenues	9,610	8,939	11,982	13,648
UNITED STATES
Revenues	12,214	6,963	19,780	10,133
UNITED STATES | Renewable Products [Member]
Revenues	5,806	2,339	12,879	4,301
UNITED STATES | Licenses and Royalties [Member]
Revenues
UNITED STATES | Grants and Collaborations [Member]
Revenues	6,408	4,624	6,901	5,832
Europe [Member]
Revenues	46,263	6,789	50,864	20,679
Europe [Member] | Renewable Products [Member]
Revenues	2,102	2,987	4,956	5,421
Europe [Member] | Licenses and Royalties [Member]
Revenues	40,964	(513)	41,082	7,442
Europe [Member] | Grants and Collaborations [Member]
Revenues	3,197	4,315	4,826	7,816
Asia [Member]
Revenues	3,899	1,113	5,867	1,791
Asia [Member] | Renewable Products [Member]
Revenues	3,899	1,113	5,617	1,791
Asia [Member] | Licenses and Royalties [Member]
Revenues
Asia [Member] | Grants and Collaborations [Member]
Revenues			250
South America [Member]
Revenues	300	194	520	215
South America [Member] | Renewable Products [Member]
Revenues	295	194	515	215
South America [Member] | Licenses and Royalties [Member]
Revenues
South America [Member] | Grants and Collaborations [Member]
Revenues	5		5
Other Area [Member]
Revenues	18		37	100
Other Area [Member] | Renewable Products [Member]
Revenues	18		37	100
Other Area [Member] | Licenses and Royalties [Member]
Revenues
Other Area [Member] | Grants and Collaborations [Member]
Revenues

Note 9 - Revenue Recognition _5

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues	$ 62,694	$ 15,059	$ 77,068	$ 32,918
All Other Customers [Member]
Revenues	14,846	4,958	24,322	9,232
Significant Revenue Agreement [Member]
Revenues	47,848	10,101	52,746	23,686
Significant Revenue Agreement [Member] | DSM International B.V. [Member]
Revenues	43,328	1,224	43,346	9,875
Significant Revenue Agreement [Member] | Givaudan International, SA [Member]
Revenues	1,240	3,467	2,815	6,043
Significant Revenue Agreement [Member] | Firmenich [Member]
Revenues	559	1,219	3,676	2,730
Significant Revenue Agreement [Member] | DARPA [Member]
Revenues	2,721	4,191	2,909	5,038
Renewable Products [Member]
Revenues	12,120	6,633	24,004	11,828
Renewable Products [Member] | All Other Customers [Member]
Revenues	10,880	4,524	19,296	8,437
Renewable Products [Member] | Significant Revenue Agreement [Member]
Revenues	1,240	2,109	4,708	3,391
Renewable Products [Member] | Significant Revenue Agreement [Member] | DSM International B.V. [Member]
Revenues			2
Renewable Products [Member] | Significant Revenue Agreement [Member] | Givaudan International, SA [Member]
Revenues	1,240	2,109	2,815	3,184
Renewable Products [Member] | Significant Revenue Agreement [Member] | Firmenich [Member]
Revenues			1,891	207
Renewable Products [Member] | Significant Revenue Agreement [Member] | DARPA [Member]
Revenues
Licenses and Royalties [Member]
Revenues	40,964	(513)	41,082	7,442
Licenses and Royalties [Member] | All Other Customers [Member]
Revenues
Licenses and Royalties [Member] | Significant Revenue Agreement [Member]
Revenues	40,964	(513)	41,082	7,442
Licenses and Royalties [Member] | Significant Revenue Agreement [Member] | DSM International B.V. [Member]
Revenues	40,682	(513)	40,302	7,405
Licenses and Royalties [Member] | Significant Revenue Agreement [Member] | Givaudan International, SA [Member]
Revenues
Licenses and Royalties [Member] | Significant Revenue Agreement [Member] | Firmenich [Member]
Revenues	282		780	37
Licenses and Royalties [Member] | Significant Revenue Agreement [Member] | DARPA [Member]
Revenues
Grants and Collaborations [Member]
Revenues	9,610	8,939	11,982	13,648
Grants and Collaborations [Member] | All Other Customers [Member]
Revenues	3,966	434	5,026	795
Grants and Collaborations [Member] | Significant Revenue Agreement [Member]
Revenues	5,644	8,505	6,956	12,853
Grants and Collaborations [Member] | Significant Revenue Agreement [Member] | DSM International B.V. [Member]
Revenues	2,646	1,737	3,042	2,470
Grants and Collaborations [Member] | Significant Revenue Agreement [Member] | Givaudan International, SA [Member]
Revenues		1,358		2,859
Grants and Collaborations [Member] | Significant Revenue Agreement [Member] | Firmenich [Member]
Revenues	277	1,219	1,005	2,486
Grants and Collaborations [Member] | Significant Revenue Agreement [Member] | DARPA [Member]
Revenues	$ 2,721	$ 4,191	$ 2,909	$ 5,038

Note 9 - Revenue Recognition _6

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Accounts receivable, net		$ 15,805	$ 16,003
Accounts receivable - related party, net		3,696	1,349
Accounts receivable, unbilled - related party			8,021
Accounts receivable, unbilled, noncurrent - related party		1,203	1,203
Contract liabilities, current		12,737	8,236
Contract liabilities, noncurrent(1)	[1]	1,449	1,587
Refund liability		$ 12,500
[1]	As of June 30, 2019 and December 31, 2018, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the consolidated balance sheets.

Note 9 - Revenue Recognition _7

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) $ in Thousands	Jun. 30, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 87,360

Note 9 - Revenue Recognition _8

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations 2 (Details) $ in Thousands	Jun. 30, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 87,360
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01
Revenue, Remaining Performance Obligation, Amount	$ 17,680
Revenue, Remaining Performance Obligation, Timing of Satisfaction, Period (Year)	182 days
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Amount	$ 38,508
Revenue, Remaining Performance Obligation, Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Amount	$ 31,172
Revenue, Remaining Performance Obligation, Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Amount
Revenue, Remaining Performance Obligation, Timing of Satisfaction, Period (Year)	1 year

Note 10 - Related Party Trans_3

Note 10 - Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounts receivable, net	$ 3,696	$ 1,349
Contract assets, current		8,021
Contract assets, noncurrent	1,203	1,203
DSM International B.V. [Member]
Accounts receivable, net	3,696	1,071
Contract assets, current		8,021
Contract assets, noncurrent	1,203	1,203
Novvi LLC [Member]
Accounts receivable, net		188
Total [Member]
Accounts receivable, net		$ 90

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - shares	Jan. 01, 2019	Dec. 31, 2018
Shares, Outstanding, Ending Balance		76,564,829
Equity Incentive Plan, 2010 [Member]
Automatic Annual Increase in the Number of Shares Available for Grant and Issuance	3,828,241
Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock	5.00%
Automatic Annual Increase in the Number of Shares Reserved for Issuance	383,824
Automatic Annual Increase in Shares Reserved for Issuance, Percentage of Outstanding Stock	0.5

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Outstanding (in shares)	5,390,270
Outstanding, weighted average exercise price (in dollars per share)	$ 11.55
Outstanding, weighted average remaining contractual life (Year)	8 years 73 days	8 years 182 days
Outstanding, aggregate intrinsic value	$ 141	$ 29
Granted (in shares)	270,633
Granted, weighted average exercise price (in dollars per share)	$ 3.67
Exercised (in shares)	(3,612)
Exercised, weighted average exercise price (in dollars per share)	$ 3.68
Forfeited or expired (in shares)	(121,753)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 10.39
Outstanding (in shares)	5,535,538	5,390,270
Outstanding, weighted average exercise price (in dollars per share)	$ 11.19	$ 11.55
Vested or expected to vest (in shares)	4,953,402
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 11.91
Vested and expected to vest, weighted average remaining contractual life (Year)	8 years 36 days
Vested and expected to vest, aggregate intrinsic value	$ 132
Exercisable (in shares)	1,202,809
Exercisable, weighted average exercise price (in dollars per share)	$ 32.99
Exercisable, weighted average remaining contractual life (Year)	6 years
Exercisable, aggregate intrinsic value	$ 29

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Outstanding, RSUs (in shares)	5,294,803
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 5.50
Outstanding, weighted average remaining contractual life (Year)	1 year 219 days	1 year 255 days
Awarded (in shares)	1,148,866
Awarded, weighted average grant-date fair value (in dollars per share)	$ 3.73
RSUs released (in shares)	(868,975)
RSUs released, weighted average grant-date fair value (in dollars per share)	$ 5.76
RSUs forfeited (in shares)	(289,952)
RSUs forfeited, weighted average grant-date fair value (in dollars per share)	$ 5.62
Outstanding, RSUs (in shares)	5,284,742	5,294,803
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 5.06	$ 5.50
Vested or expected to vest (in shares)	4,913,990
Vested or expected to vest, weighted average grant-date fair value (in dollars per share)	$ 5.07
Vested or expected to vest, weighted average remaining contractual life (Year)	1 year 182 days

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Allocated share-based compensation expense	$ 3,375	$ 1,900	$ 6,827	$ 3,178
Research and Development Expense [Member]
Allocated share-based compensation expense	676	333	1,339	696
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 2,699	$ 1,567	$ 5,488	$ 2,482

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)

Sep. 23, 2019

Sep. 16, 2019

Sep. 10, 2019

Aug. 14, 2019

Aug. 08, 2019

Jul. 30, 2019

Jul. 26, 2019

Jul. 24, 2019

Jul. 08, 2019

Jun. 24, 2019

May 15, 2019

May 14, 2019

Apr. 26, 2019

Jun. 30, 2020

Oct. 01, 2019

Sep. 30, 2019

Sep. 29, 2019

Sep. 19, 2019

Sep. 17, 2019

Aug. 29, 2019

Aug. 28, 2019

Jul. 29, 2019

Jul. 10, 2019

Jun. 30, 2019

Dec. 31, 2018

Dec. 10, 2018

Aug. 17, 2018

Long-term Debt, Total

$ 168,744,000

$ 209,697,000

Long-term Debt, Gross

167,360,000

228,921,000

Warrants Issued in Exchange for August 2013 Financing Convertible Note [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,080,000

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

4.99%

July Foris Credit Agreement [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 7.52

July Foris Credit Agreement [Member] | Subsequent Event [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.87

August Foris Credit Agreement [Member] | Subsequent Event [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

4,871,795

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

19.99%

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 3.90

Class of Warrant or Right, Term

2 years

Private Placement, April 26, 2019 [Member] | Foris Ventures, LLC [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.12

$ 3.90

Class of Warrant or Right, Term

2 years

Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

4.99%

Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member] | Foris Ventures, LLC [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 4.56

$ 3.90

Class of Warrant or Right, Term

2 years

Debt Conversion, Original Debt, Amount

$ 10,000,000

Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

181,818

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.12

Debt Instrument, Repayment Price, Percent of Face Amount

4.99%

Class of Warrant or Right, Term

2 years

Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member] | Subsequent Event [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

2,000,000

Warrants Issued in Exchange for Convertible Senior Notes, 6.0% Due 2021, Second Exchange [Member] | Subsequent Event [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.87

Class of Warrant or Right, Term

2 years

LSA Amendment Warrants [Member] | Subsequent Event [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,438,829

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.87

Warrants and Rights Outstanding, Term

2 years

Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage

19.99%

Investors Warrants [Member] | Subsequent Event [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

3,205,128

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 3.90

Warrants and Rights Outstanding, Term

2 years

Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage

9.99%

Warrants or Rights Outstanding, Reduction in Exercise Price

10.00%

Warrants or Rights Outstanding, Additional Reduction in Exercise Price

5.00%

Investors Warrants [Member] | Subsequent Event [Member] | Minimum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 3.31

Convertible Debt [Member]

Long-term Debt, Total

77,234,000

120,874,000

Long-term Debt, Gross

62,832,000

126,306,000

August 2013 Convertible Notes [Member] | Convertible Debt [Member]

Debt Conversion, Converted Instrument, Shares Issued

1,767,632

Long-term Debt, Total

4,773,000

4,345

Long-term Debt, Gross

4,863,000

$ 4,415,000

July Foris Credit Agreement [Member] | Foris Ventures, LLC [Member] | Subsequent Event [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 16,000,000

Long-term Line of Credit, Total

$ 8,000,000

8,000,000

Debt Instrument, Face Amount

$ 8,000,000

$ 8,000,000

Debt Instrument, Interest Rate, Stated Percentage

12.50%

12.50%

Foris Credit Agreements [Member] | Foris Ventures, LLC [Member] | Subsequent Event [Member]

Debt Instrument, Repayment Price, Percent of Face Amount

100.00%

August Foris Credit Agreement [Member] | Foris Ventures, LLC [Member] | Subsequent Event [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 19,000,000

Debt Instrument, Face Amount

$ 19,000,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Repayment Price, Percent of Face Amount

100.00%

Convertible Senior Notes, 6.0% Due in 2021 [Member]

Debt Instrument, Face Amount

$ 60,000,000

Debt Instrument, Interest Rate, Stated Percentage

6.00%

6.00%

6.00%

Debt Instrument, Repayment Price, Percent of Face Amount

125.00%

125.00%

Debt Conversion, Original Debt, Amount

$ 4,700,000

$ 4,700,000

$ 53,300,000

Long-term Debt, Gross

58,000,000

Convertible Senior Notes, 6.0% Due in 2021 [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 68,300,000

Debt Conversion, Original Debt, Amount

$ 53,300,000

Debt Instrument, Penalty for Failure to Make Payment, Premium Increase Percentage

25.00%

Debt Instrument, Periodic Payment, Principal

$ 6,400,000

Convertible Senior Notes, 6.0% Due in 2021 [Member] | Convertible Debt [Member]

Long-term Debt, Total

72,461,000

$ 57,918,000

Long-term Debt, Gross

$ 57,969,000

$ 60,000,000

Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 68,300,000

Debt Instrument, Interest Rate, Stated Percentage

18.00%

Debt Instrument, Periodic Payment, Principal

$ 3,200,000

Debt Instrument, Debt Default, Amount

$ 63,600,000

Extinguishment of Debt, Amount

$ 143,700,000

Nikko Loan Agreement [Member] | Subsequent Event [Member]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Long-term Debt, Total

$ 5,000,000

Nikko Loan Agreement [Member] | Subsequent Event [Member] | Nikko [Member] | Aprinnova JV [Member]

First Priority Lien on Interests Owned by the Company

12.80%

Nikko Loan Agreement, First Installment [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 3,000,000

Proceeds from Issuance of Long-term Debt, Total

2,800,000

Nikko Loan Agreement, First Installment [Member] | Subsequent Event [Member] | Nikko [Member]

Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable

$ 200,000

Nikko Loan Agreement, Second Installment [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 2,000,000

Proceeds from Issuance of Long-term Debt, Total

1,900,000

Nikko Loan Agreement, Second Installment [Member] | Subsequent Event [Member] | Nikko [Member]

Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable

$ 100,000

Loan and Security Agreement Amendment and Waiver [Member] | Subsequent Event [Member]

Debt Instrument, Interest Rate, Stated Percentage

4.75%

Long-term Debt, Gross

$ 71,000,000

Loan and Security Agreement Amendment and Waiver [Member] | Subsequent Event [Member] | Base Rate [Member] | Minimum [Member]

Debt Instrument, Basis Spread on Variable Rate

9.00%

Loan and Security Agreement Amendment and Waiver [Member] | Subsequent Event [Member] | Base Rate [Member] | Maximum [Member]

Debt Instrument, Basis Spread on Variable Rate

12.00%

Loan and Security Agreement Amendment and Waiver [Member] | Unsecured Promissory Note [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 32,500,000

The Naxyris Loan Agreement [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 10,435,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Failure to Pay Fee

6.00%

The Naxyris Loan Agreement [Member] | Subsequent Event [Member] | Interest Wtih Respect to Indebtedness [Member]

Debt Instrument, Basis Spread on Variable Rate

0.25%

The 2019 DSM Credit Agreement [Member] | DSM International B.V. [Member] | Forecast [Member]

Proceeds from Sale of Equity Securities, Gross, Trigger Repayment of Amounts Outstanding Under Line of Credit

$ 50,000,000

The 2019 DSM Credit Agreement [Member] | DSM International B.V. [Member] | Subsequent Event [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 8,000,000

Debt Instrument, Interest Rate, Stated Percentage

12.50%

The 2019 DSM Credit Agreement, First Installment [Member] | DSM International B.V. [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 3,000,000

Line of Credit Facility, Incremental Draw Down Amount

3,000,000

The 2019 DSM Credit Agreement, Second Installment [Member] | DSM International B.V. [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 3,000,000

Line of Credit Facility, Incremental Draw Down Amount

$ 3,000,000

3,000,000

The 2019 DSM Credit Agreement, Third Installment [Member] | DSM International B.V. [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 2,000,000

Line of Credit Facility, Incremental Draw Down Amount

2,000,000

$ 2,000,000

Extinguishment of Debt, Amount

$ 1,500,000

Investor Credit Agreements [Member] | The Investor Notes [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 12,500,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Secured Promissory Note In Connection With Termination of Ginkgo Collaboration Agreement [Member] | Subsequent Event [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

10.50%

Debt Instrument, Cash Waiver Fee Amount Payable

$ 1,300,000